Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 13754. Отображено 100.
26-01-2012 дата публикации

3-aminoxalyl-aminobenzamide derivatives and insecticidal and miticidal agents containing same as active ingredient

Номер: US20120022263A1
Принадлежит: Agro Kanesho Co Ltd

The present invention herein provides a 3-aminooxalylaminobenzamide derivative which is used as an insecticide or miticide. The 3-aminooxalylaminobenzamide derivative is one represented by the following general formula [1]: (R 1 and R 2 each represent, for instance, a C 1 to C 3 alkoxy group or a C 1 to C 3 haloalkoxy group; R 3 and R 4 each represent, for instance, a C 1 to C 8 alkyl group or a C 1 to C 8 haloalkyl group; R 5 represents, for instance, a C 1 to C 5 haloalkyl group; R 6 and R 7 each represent, for instance, a hydrogen atom or a C 1 to C 5 alkyl group; Y represents, for instance, a hydrogen atom or a halogen atom; Z represents, for instance, a hydrogen atom; n is an integer ranging from 0 to 4 and m is an integer ranging from 0 to 2).

Подробнее
02-02-2012 дата публикации

Novel lipids and compositions for the delivery of therapeutics

Номер: US20120027796A1
Принадлежит: Alnylam Pharmaceuticals Inc

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures: (Formula (I) or (XXXV)).

Подробнее
02-02-2012 дата публикации

Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products

Номер: US20120029013A1
Принадлежит: Pierre Fabre Medicament SA

The present invention concerns compounds of general formula (1), where in:—-a- is a single or double bond, Ar is an aromatic group, substituted or unsubstituted, R1 and R2 each independently or together are: a hydrogen atom or C 1 -C 6 alkyl group, branched or unbranched, saturated or unsaturated, substituted or unsubstituted; the groups R1 and R2 may also form a heterocycle, R3 and R3′ each independently or together are a hydrogen atom or C 1 -C 6 alkyl group, X is an oxygen atom or a sulphur atom, and the addition salts of the compounds of general formula (1) with pharmaceutically acceptable mineral acids or organic acids.

Подробнее
02-02-2012 дата публикации

Synthesis of enone intermediate

Номер: US20120029199A1
Принадлежит: Harvard College

The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides a more efficient route for preparing the enone intermediate.

Подробнее
16-02-2012 дата публикации

Hydrophobic monomers, hydrophobically-derivatized supports, and methods of making and using the same

Номер: US20120039920A1
Принадлежит: 3M Innovative Properties Co

A composition is disclosed comprising a hydrophobic monomer having the structure: CH 2 ═CR 4 C(O)NHC(R 1 R 1 )(C(R 1 R 1 )) n C(O)XR 3 wherein n is an integer of 0 or 1; R 1 is independently selected from at least one of: a hydrogen atom, alkyls aryls, and alkylaryls, wherein the alkyls, aryls, and alkylaryls have a total of 10 carbon atoms or less; R 3 is a hydrophobic group selected from at least one of: alkyls, aryls, alkylaryls and ethers, wherein the alkyls, aryls, alkylaryls and ethers have a total number of carbon atoms ranging from 4 to 30; R 4 H or CH 3 ; X is O or NH. In some embodiments the hydrophobic monomer is derived from an amine or an alcohol (HXR 3 ) that has a hydrophilicity index of 25 or less. A polymerizable composition comprising the hydrophobic monomer is disclosed, which optionally may comprise a cross-linking monomer and/or a non-cross-linking monomer. This polymerizable mixture may be used to from hydrophobically-derivatized supports, which may be used in applications such as hydrophobic interaction chromatography.

Подробнее
23-02-2012 дата публикации

Diacylethylenediamine compound

Номер: US20120046292A1
Принадлежит: Astellas Pharma Inc

[Problem] A compound which is useful as an anti-obesity agent is provided. [Means for Solution] The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of the present invention has an excellent DGAT1 inhibitory action, thereby completing the present invention. That is, the diacylethylenediamine compound of the present invention has a DGAT1 inhibitory action, and can be therefore used as an agent for preventing and/or treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases.

Подробнее
22-03-2012 дата публикации

Metallo-beta-lactamase inhibitors

Номер: US20120071457A1
Принадлежит: Individual

A new metallo-β-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of β-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-β-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of β-lactam antibiotics against metallo-β-lactamase producing bacteria by combining the compound of the general formula (I) with β-lactam antibiotics.

Подробнее
29-03-2012 дата публикации

Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response

Номер: US20120077858A1
Принадлежит: Allergan Inc

The present invention provides compounds, that are N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfonamido)propyl)benzyl)pyrrolidin-2-yl)oxazole-4-carboxamide wherein the 5 substituent is selected from the group consisting of halo and alkyloxy radicals. The compound may be represented by the following formula wherein R 1 is selected from the group consisting of CO 2 R 7 and CON(R 7 )SO 2 R 7 wherein R 1 , R 2 , R 3 , R 4 , and R 7 are as defined in the specification. The compounds may be administered to treat DP 1 , FP, EP 1 , EP 3 , TP and/or EP 4 receptor mediated diseases or conditions.

Подробнее
19-04-2012 дата публикации

Novel lipids and compositions for the delivery of therapeutics

Номер: US20120095075A1
Принадлежит: Alnylam Pharmaceuticals Inc

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure:

Подробнее
17-05-2012 дата публикации

Substituted carbamoylcycloalkyl acetic acid derivatives as nep

Номер: US20120122764A1
Принадлежит: NOVARTIS AG

The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , B, X, m and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of compounds of the invention, and a combination of pharmacologically active agents and a compound of the invention.

Подробнее
24-05-2012 дата публикации

Dual-acting antihypertensive agents

Номер: US20120129900A1
Принадлежит: Theravance Inc

The invention is directed to compounds of formula I: wherein Ar, r, R 3 , X, and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.

Подробнее
07-06-2012 дата публикации

Compounds as bradykinin b1 antagonists

Номер: US20120142695A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds of the formula I wherein n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and X are defined as described in the specification, which are bradykinin B1 antagonists, and their use as medicaments.

Подробнее
07-06-2012 дата публикации

Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States

Номер: US20120142781A1
Автор: Ibert Clifton Wells
Принадлежит: Magnesium Diagnostics Inc

This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.

Подробнее
14-06-2012 дата публикации

Enzyme inhibitors

Номер: US20120149736A1
Принадлежит: Chroma Therapeutics Ltd

Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent ═CH— or ═N—; W is —CH═CH— Or —CH 2 CH 2 —; R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intra-cellular carboxylesterase enzymes to a carboxylic acid group; R2 and R3 are selected from the side chains of a natural or non-nat-ural alpha amino acid, provided that neither R2 nor R3 is hydrogen, or R2 and R3, taken together with the carbon to which they are attached, form a 3-6 membered saturated cycloalkyl or heterocyclyl ring; Y is a bond, —C(═O)—, —S(═O)2—, —C(═O)O—, —C(═O)NR′—, —C(═5)—NR′, —C(═NH)NR′ or —S(═O) 2 NR — wherein R′ is hydrogen or optionally substituted C 1 —C 6 alkyl; L 1 is a divalent radical of formula —(Alk 1 ) m ,(Q) n (Alk 2 ) p — wherein m, n, p, Q, Alk 1 and Alk 2 are as defined in the claims; X 1 represents a bond; —C(═O); or —S(═O) 2 —; —NR 4 C(═O)—, —C(═O)NR 4 —,— NR 4 C(═O)NR 5 —, —NR 4 S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R4 and R5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; and z is 0 or 1.

Подробнее
28-06-2012 дата публикации

Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists

Номер: US20120165360A1
Принадлежит: Theravance Inc

The invention provides amino- and amido-aminotetralin compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

Подробнее
28-06-2012 дата публикации

Novel compound and method for preparing the same

Номер: US20120165572A1
Принадлежит: Fujifilm Corp

The invention is directed to a compound represented by the Formula (1) as defined herein, and a method for preparing a compound represented by the Formula (1) which includes: reacting a diamine compound represented by the Formula (2) as defined herein with a methacrylic anhydride or an acrylic anhydride under a condition where an organic acid having a pKa of 2.0 or more is present in an amount of 0.5 to 5.0 moles based on 1 mole of the diamine compound to obtain a reaction mixture; adding phosphoric acid to the reaction mixture; and purifying the reaction mixture by extraction with an organic solvent.

Подробнее
05-07-2012 дата публикации

Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives

Номер: US20120172426A1
Принадлежит: Reviva Pharmaceuticals Inc

The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.

Подробнее
26-07-2012 дата публикации

Aflatoxin production inhibitor and method for controlling aflatoxin contamination using the same

Номер: US20120190746A1

The present invention relates to provide an aflatoxin production inhibitor that inhibits aflatoxin production specifically and efficiently, is highly safe, and is practical, and an efficient production method thereof; and a method for controlling aflatoxin contamination that uses the aflatoxin production inhibitor, specifically relating to an aflatoxin production inhibitor that includes at least one of a dioctatin represented by the following formula (I) and a derivative thereof, as an active ingredient: where, in the formula (I), R represents one of hydrogen and a methyl group.

Подробнее
09-08-2012 дата публикации

Substituted 4-aminocyclohexane derivatives

Номер: US20120202810A1
Принадлежит: GRUENENTHAL GmbH

The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

Подробнее
23-08-2012 дата публикации

New compounds, pharmaceutical compositions and uses thereof

Номер: US20120214782A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Подробнее
23-08-2012 дата публикации

New compounds, pharmaceutical compositions and uses thereof

Номер: US20120214785A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Подробнее
30-08-2012 дата публикации

2-phenylethylamino derivatives as calcium and/or sodium channel modulators

Номер: US20120220592A1
Принадлежит: Newron Pharmaceuticals SpA

2-Phenylethylamino substituted carboxamide derivatives and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies are presented.

Подробнее
06-09-2012 дата публикации

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease

Номер: US20120225890A1
Принадлежит: ProteoTech Inc

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Подробнее
20-09-2012 дата публикации

Treatment of cancer

Номер: US20120238601A1
Принадлежит: BiPar Sciences Inc

The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.

Подробнее
25-10-2012 дата публикации

Small molecules that covalently modify transthyretin

Номер: US20120270938A1
Принадлежит: Scripps Research Institute

A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and reacts chemoselectively with one or two of four Lys-15 ε-amino groups within the transthyretin tetramer. The crystal structure confirms the binding orientation of the compound substructure and the conjugating amide bond. A covalent transthyretin kinetic stabilizer exhibits superior amyloid inhibition potency, compared to a non-covalent counterpart, and inhibits cytotoxicity associated with amyloidogenesis.

Подробнее
24-01-2013 дата публикации

Arachidonic acid analogs and methods for analgesic treatment using same

Номер: US20130023510A1
Принадлежит: Cytometix Inc

The present invention provides arachidonic acid (AA) analogs and compositions containing those analogs as active agents for use in analgesic treatments. Various methods of manufacturing the inventive compounds are provided and pharmaceutical formulations, including injectable and oral dosages, are described. Certain analogs are additionally useful as antipyretic compositions and in related fever reducing treatments.

Подробнее
31-01-2013 дата публикации

Methods and compounds for the targeted delivery of agents to bone for interaction therewith

Номер: US20130029901A1

Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (R T ), having an affinity for bone; a Bone Active Portion (R A ) for interacting with and affecting bone; and a Linking Portion (R L ) connecting the Bone Targeting Portion and the Bone Active Portion.

Подробнее
31-01-2013 дата публикации

Process for the preparation of lacosamide

Номер: US20130030216A1
Принадлежит: EUTICALS SPA

A novel process for the synthesis of Lacosamide using D,L-serine as starting material is described, where the methylation reaction of hydroxyl is carried out using an inexpensive base such as NaOH and an inexpensive alkylating agent, non-toxic and non-carcinogenic, such as methyl p-toluenesulfonate; the R enantiomer is isolated from the racemic mixture of Lacosamide after selective hydrolysis of the acetamide, salification of the racemic mixture with a chiral acid (HX*) in an organic solvent, resolution of the diastereoisomeric mixture, preferably by precipitation of the R enantiomer, and subsequent acetylation of the optically pure intermediate.

Подробнее
07-02-2013 дата публикации

Therapeutic peptides

Номер: US20130035296A1
Принадлежит: LYTIX BIOPHARMA AS

The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted β amino acid, each of the substituting groups in the β amino acid, which may be the same or different, comprises at least (7) non-hydrogen atoms, is lipophilic and has at least one cyclic group, one or more cyclic groups within a substituting group may be linked or fused to one or more cyclic groups within the other substituting group and where cyclic groups are fused in this way the combined total number of non-hydrogen atoms for the two substituting groups is at least (12), for use as a cytolytic therapeutic agent; as well as non therapeutic uses of these molecules and certain defined novel compounds from within this definition.

Подробнее
07-02-2013 дата публикации

Pyrrolysine analogs

Номер: US20130035478A1
Принадлежит: Ohio State University

Several different pyrrolysine analogs are disclosed in this application. Those analogs have distinct chemical and biophysical properties. Some analogs are useful in chemical ligation applications. Methods of making and using are also disclosed.

Подробнее
21-02-2013 дата публикации

Salicylate fatty acid derivatives

Номер: US20130046013A1
Принадлежит: Individual

Fatty acid conjugates of salicylate derivatives and compositions thereof are disclosed. Further disclosed are methods for treating various diseases comprising the administration of an effective amount of at least one compound according to the present disclosure.

Подробнее
28-02-2013 дата публикации

Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use

Номер: US20130053412A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The invention relates to cyclopentanecarboxamide derivatives of formula 1, to their use as Fatty Acid Synthase inhibitors, to methods for their therapeutic use and to pharmaceutical compositions containing them, wherein R 1 , R 2 , R 3 , LO, W, AR 1 , n are as defined in claim 1 .

Подробнее
28-03-2013 дата публикации

Lipid Compounds Targeting VLA-4

Номер: US20130079383A1
Принадлежит: ARROWHEAD RESEARCH CORPORATION

The invention relates to the compounds of formula I: 8. A compound of wherein W is hydrogen and Y is methyl.9. A compound of wherein both W and Y are methyl.10. A compound of wherein Ris an alkyl having 9-20 carbon atoms.11. A compound of wherein Ris an alkyl having 16-20 carbon atoms.12. A compound of wherein Ris an alkyl having 18 carbon atoms.13. A compound of wherein Ris an alkyl having 19 carbon atoms.14. A compound of wherein Ris an alkyl having 20 carbon atoms.15. A compound of wherein n is 9-13.16. A compound of selected from the group consisting of:[2,3-bis(dodecyloxy)propyl][3-[[3-[2-[2-[2-[2-[2-[2-[2-[2-[[3-[[2-[1-[[[(S)-1-carboxy-2-[4-(2,6-dichloro-benzoylamino)phenyl]ethyl]amino]carbonyl]cyclopentyl]ethyl]amino]-3-oxopropyl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]propyl]dimethylaminium trifluoroacetate;[2,3-bis(dodecyloxy)propyl][3-[[4-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[3-[[2-[1-[[[(S)-1-carboxy-2-[4-(2,6-dichloro-benzoylamino)phenyl]ethyl]amino]carbonyl]cyclopentyl]ethyl]amino]-3-oxopropyl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]amino]-1-4-dioxobutyl]amino]propyl]dimethylaminium trifluoroacetate;[[2,3-bis(hexadecyloxy)propyl][3-[[3-[2-[2-[2-[2-[2-[2-[2-[2-[[3-[[2-[1-[[[(S)-1-carboxy-2-[4-(2,6-dichloro-benzoylamino)phenyl]ethyl]amino]carbonyl]cyclopentyl]ethyl]amino]-3-oxopropyl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]propyl]dimethylaminium trifluoroacetate;[2,3-bis(hexadecyloxy)propyl][3-[[4-[[2-2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[3-[[2-[1-[[[(S)-1-carboxy-2-[4-(2,6-dichloro-benzoylamino)phenyl]ethyl]amino]carbonyl]cyclopentyl]ethyl]amino]-3-oxopropyl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]amino]-1,4-dioxobutyl]amino]propyl]dimethylaminium trifluoroacetate;(S)-Alpha-[[[1-[2-[[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[4-[[3-[[2,3-bis(hexadecyloxy)propyl]methylamino]propyl]amino]-1,4- ...

Подробнее
28-03-2013 дата публикации

"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS"

Номер: US20130079514A1
Принадлежит: Dompé S.p.A.

(R)-2-Arylpropionamide compounds of formula (I), pharmaceutical preparations of the compounds and a process for making the compounds are described. 2. The composition claim according to claim 1 , wherein the compound of the formula I has activity as an inhibitor of IL-8 induced chemotaxis of polymorphonucleate leukocytes.3. The composition of claim 1 , containing said compound in an amount effective for the treatment of a pathology selected from the group consisting of psoriasis claim 1 , pemphigus and pemphigoid claim 1 , rheumatoid arthritis claim 1 , intestinal chronic inflammatory pathologies claim 1 , acute respiratory distress syndrome claim 1 , idiopathic fibrosis claim 1 , cystic fibrosis claim 1 , chronic obstructive pulmonary disease and glomerulonephritis.4. The composition of claim 1 , wherein X together with the nitrogen atom of the omega-amino group to which it is bound and with the R1 and R2 groups forms a non-aromatic nitrogen containing ring selected from 1-methyl-piperydin-4-yl and N-exo-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl.5. The composition according to claim 1 , wherein said compound of formula (I) is selected from the group consisting of(R)-2-[(4-isobutyl)phenyl]-N-(1-methylpiperidin-4-yl)propionamide;(R)-2-[(4-isobutyl)phenyl]-N(exo-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)propionamide. This application is a Divisional application that claims priority under 35 U.S.C. §120 of application Ser. No. 10/469,094 filed on Aug. 25, 2003, and application Ser. No. 10/469,094 is the National Phase under 35 U.S.C. §371 of International Application No. PCT/EP2002/001974 filed on Feb. 25, 2002, which claims priority under 35 U.S.C. §119(a-d) of Application No. MI2001A000395 filed in the Italian Patent Office on Feb. 27, 2001. All of these applications are hereby incorporated by reference for all purposes.The present invention relates to omega-aminoalkylamides of (R) 2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate ...

Подробнее
11-04-2013 дата публикации

LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE

Номер: US20130090386A1
Принадлежит:

The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A′), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CHC(=0)NH, heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is —NH—; (L) is chosen from a single bond, —CH—, —CHCH—, —CHCHCH—, and —CHCHCHCH—; and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from —NH, —NH(C-Calkyl), —N(C-Calkyl)(C-Calkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy. (A′)X-(A)-(B)—(Z)-(L)-(D) formula (I) The compounds of the invention show activity for inhibiting LSD1, which makes them useful in the treatment or prevention of diseases such as cancer. 1. A compound of Formula 1{'br': None, 'sub': 'X', '(A′)-(A)-(B)—(Z)-(L)-(D)\u2003\u20031'} (A) is heteroaryl or aryl;', {'sub': 2', '2, 'each (A′), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CHC(═O)NH, heteroaryl, cyano, sulfonyl, and sulfinyl;'}, 'X is 0, 1, 2, or 3;', '(B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B);', '(Z) is —NH—;', {'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '2, '(L) is chosen from a single bond, —CH—, —CHCH—, —CHCHCH—, and —CHCHCHCH—; and'}, {'sub': 2', '1', '6', '1', '6', '1', ...

Подробнее
18-04-2013 дата публикации

POLYANIONIC MULTIVALENT MACROMOLECULES FOR INTRACELLULAR TARGETING OF PROLIFERATION AND PROTEIN SYNTHESIS

Номер: US20130095035A1
Принадлежит: MIVENION GMBH

The present invention relates generally to methods and compositions for targeting of intracellular molecules involved in proliferation and protein synthesis of activated cells using polyanionic multivalent macromolecules. In particular aspect, multiple sulfate groups linked to polyol are specifically targeted to the cytoplasm and nucleus of proliferating and activated cells. The invention further comprises novel polyanionic macromolecular compounds and formulations. 1. Pharmaceutical composition comprising a sulfated polyglycerol and a therapeutic or diagnostic effector molecule that is covalently conjugated to said sulfated polyglycerol.2. Pharmaceutical composition according to of the formula P(OSOM)(L-G-E)with P is a polyol macromolecule wherein a number n of hydroxyl groups is substituted by sulfate groups OSOM claim 1 , M is a cationic inorganic or organic counter ion to the anionic sulfate group claim 1 , E is therapeutic or diagnostic effector molecule claim 1 , L is a linker or spacer between P and E claim 1 , G is a reactive group for the covalent attachment between L and E claim 1 , and m is a number of 1-100.3. Pharmaceutical composition according to for treating a disease by intracellular uptake of said sulfated polyglycerol and a therapeutic or diagnostic effector molecule into activated cells or proliferative cells and by inhibiting NF-kappaB and/or AP-1 and/or inhibiting TGF-beta synthesis in said cells.4. Conjugate comprising a sulfated polyglycerol and a therapeutic or diagnostic effector molecule that is covalently conjugated to said sulfated polyglycerol.5. Conjugate according to of the formula P(OSOM)(L-G-E)with P is a polyol macromolecule wherein a number n of hydroxyl groups is substituted by sulfate groups OSOM claim 4 , M is a cationic inorganic or organic counter ion to the anionic sulfate group claim 4 , E is therapeutic or diagnostic effector molecule claim 4 , L is a linker or spacer between P and E claim 4 , G is a reactive group for the ...

Подробнее
18-04-2013 дата публикации

SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS

Номер: US20130096127A1
Принадлежит: NOVARTIS AG

The present invention provides a compound of formula I′; 3. The compound of wherein:{'sup': '1', 'sub': '1-7', 'Ris H or Calkyl;'}{'sup': 2', 'a', 'b', 'a', 'b, 'sub': 1-7', '3-7', '1-7', '1-7', '6-20', '1-7, 'Rfor each occurrence, is independently Calkyl, halo, Ccycloalkyl, hydroxy, Calkoxy, haloCalkyl, —NRR, Caryl, heteroaryl or heterocyclyl; wherein Rand Rfor each occurrence are independently H or Calkyl;'}{'sup': 3', '1', '1, 'Ris A-C(O)X;'}{'sup': '5', 'Ris H; and'}{'sup': 1', 'a', 'b, 'sub': '1-7', 'X and Xare independently OH, —O—Calkyl or NRR;'}{'sup': '1', 'Bis —C(O)NH— or —NHC(O)—;'}{'sup': '1', 'sub': 1-7', '3-7', '1-7', '3-7, 'Ais a linear or branched Calkylene; which is optionally substituted with one or more substituents independently selected from the group consisting of halo, Ccycloalkyl, Calkoxy, hydroxy and O-acetate; in which two geminal alkyl can optionally combine to form a Ccycloalkyl; or'}and wherein each heteroaryl is a monocyclic or bicyclic aromatic ring comprising 5-10 ring atoms selected from carbon atoms and 1 to 5 heteroatoms, and', 'each heterocyclyl is a monocyclic saturated or partially saturated but non-aromatic moiety comprising 4-7 ring atoms selected from carbon atoms and 1-5 heteroatoms, wherein each heteroatom of a heteroaryl or a heterocyclyl is independently selected from O, N and S, or a pharmaceutically acceptable salt thereof., 'n is 0, 1, 2, 3, 4 or 5;'}6. The compound of wherein Ais an optionally substituted linear or branched Calkylene claim 1 , or a pharmaceutically acceptable salt thereof.7. The compounds of wherein Ais CHCH claim 1 , or a pharmaceutically acceptable salt thereof.810-. (canceled)11. The compound of wherein Ris H claim 1 , Ris independently halo claim 1 , Calkoxy claim 1 , hydroxy claim 1 , Calkyl or halo-Calkyl claim 1 , n is 0 claim 1 , 1 or 2 and X and Xare independently OH or —O—Calkyl claim 1 , or a pharmaceutically acceptable salt thereof.12. The compounds of wherein n is 1 or 2; Ris meta-chloro ...

Подробнее
18-04-2013 дата публикации

N-ACYL AMINO ACID DERIVATIVES FOR TREATING SKIN CONDITIONS SUCH AS CELLULITE

Номер: US20130096143A1
Принадлежит: HELIX BIOMEDIX, INC.

The invention relates to small molecules having biological and therapeutic activity. Particularly, the invention relates to small molecules having lipolytic and anti-adipogenic activity. Two examples of such molecules are 4-methyl-2-(octanoylamino) pentanoic acid and N-isopentyloctanamide. The invention further relates to methods of preventing or treating skin conditions such as cellulite using small molecules having lipolytic and anti-adipogenic activity. 1. A composition for use in treating the skin of a mammal , said composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound or pharmaceutically acceptable salts thereof , wherein the compound comprises the formula:{'br': None, 'sub': 1', '2, 'R—C(O)—NH—R; wherein'}{'sub': '1', 'Rcomprises a chain of 5 to 35 carbon atoms,'}{'sub': '1', 'the R—C(O) portion of the formula is a fatty acyl group, and'}{'sub': '2', 'the NH—Rportion of said formula comprises{'sub': '2', '(i) an amino acid, wherein the Rgroup comprises the alpha-carbon, carboxyl group and side group of said amino acid, and wherein the NH group is linked to the alpha-carbon of said amino acid; or'}{'sub': '2', '(ii) an analog of said amino acid, wherein said analog differs from said amino acid by lacking the carboxylic group linked to the amino acid alpha-carbon, wherein the Rgroup comprises the alpha-carbon and side group of said amino acid, and wherein the NH group is linked to the alpha-carbon of said analog.'}2. The composition of claim 1 , wherein the side group of said amino acid is hydrophobic.3. The composition of claim 1 , wherein said amino acid is leucine claim 1 , isoleucine claim 1 , valine claim 1 , or alanine.83. The composition of any one of - claims 1 , wherein the chain of Rcomprises 7 to 21 carbon atoms.93. The composition of any one of - claims 1 , wherein the fatty acyl group is an octanoyl group.10. The composition of any one of claims 1 , claims 1 , and claims 1 , wherein ...

Подробнее
25-04-2013 дата публикации

TARGETED NITROXIDE AGENTS

Номер: US20130102626A1
Принадлежит:

Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation. 45-. (canceled)6. The compound of claim 1 , in which R is Ac claim 1 , Boc claim 1 , Cbz claim 1 , or —P(O)-Ph.7. The compound of claim 1 , in which R claim 1 , R claim 1 , Rand Rare independently chosen from hydrogen claim 1 , methyl claim 1 , ethyl claim 1 , propyl claim 1 , 2-propyl claim 1 , butyl claim 1 , t-butyl claim 1 , pentyl claim 1 , hexyl claim 1 , benzyl claim 1 , hydroxybenzyl claim 1 , phenyl and hydroxyphenyl.8. The compound of claim 1 , wherein when X is —CH═CR— claim 1 , Ris hydrogen claim 1 , methyl or ethyl.912-. (canceled)13. The compound of in which R1 claim 1 , R2 and R3 independently are methyl claim 1 , ethyl claim 1 , propyl claim 1 , 2-propyl claim 1 , butyl claim 1 , t-butyl claim 1 , pentyl claim 1 , hexyl claim 1 , benzyl claim 1 , hydroxybenzyl claim 1 , phenyl and hydroxyphenyl.1421-. (canceled)27. A method of making a targeted antioxidant compound claim 1 , comprising:{'sub': 1', '1', '1', '6', '6', '5, 'a. reacting an aldehyde of structure R—C(O)— with (R)-2-methylpropane-2-sulfinamide to form an imine, in which Ris C-Cstraight or branched-chain alkyl, optionally including a phenyl (CH) group, that optionally is methyl-, hydroxyl- or fluoro-substituted;'}{'sub': 2', '2', '2, 'b. reacting a terminal alkyne-1-ol (HCC—R—CH—OH), in which Ris not present or is branched or straight-chained alkylene, with a tert-butyl)diphenylsilane salt to produce an alkyne;'}c. ...

Подробнее
25-04-2013 дата публикации

SUBSTITUTED BIARYL ALKYL AMIDES

Номер: US20130102649A1
Принадлежит: BioTheryX, Inc.

Disclosed herein are substituted biaryl alkyl amide compounds, methods of synthesizing substituted biaryl alkyl amide compounds and methods of treating diseases and/or conditions with substituted biaryl alkyl amide compounds. 2. The compound of claim 1 , wherein n is selected from the group consisting of 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 claim 1 , and 5.3. The compound of claim 2 , wherein n is 2.4. The compound of claim 1 , wherein each Ris halo.5. The compound of claim 4 , wherein each Ris chloro.6. The compound of claim 1 , wherein Z claim 1 , Z claim 1 , Zand Zare each —CH—.7. The compound of claim 1 , wherein Ris (Calkoxy)Calkyl.8. The compound of claim 7 , wherein Ris methoxymethyl or ethoxymethyl.9. The compound of claim 1 , wherein Ris (aryloxy)Calkyl.10. The compound of claim 9 , wherein Ris phenoxymethyl.11. The compound of claim 1 , wherein Ris Cheterocyclyl.12. The compound of claim 11 , wherein Ris selected from optionally substituted tetrahydrofuranyl or optionally substituted pyrrolidinyl.13. The compound of claim 12 , wherein the nitrogen atom in pyrrolidinyl is protected with a t-butyloxycarbonyl (Boc) protecting group.14. The compound of claim 1 , wherein Ris Ccycloalkyl.15. The compound of claim 14 , wherein Ris cyclopentyl.16. The compound of claim 1 , wherein Ris haloalkyl.17. The compound of claim 16 , wherein Ris selected from the group consisting of —CHCl claim 16 , —CHBr claim 16 , —CHCHCl claim 16 , —CHCHBr claim 16 , —CH(Cl)CHand —CH(Br)CH.18. The compound of claim 1 , wherein Ris optionally substituted aminoalkyl.19. The compound of claim 18 , wherein Ris selected from the group consisting of —CHNH claim 18 , —CHNH(Boc) claim 18 , —CH(NH)CH claim 18 , and —CH(Boc-NH)CH.20. The compound of claim 1 , wherein Ris —OH.22. The compound of claim 21 , wherein Ris —OH.23. The compound of claim 1 , wherein Ris selected from the group consisting of —OH claim 1 , —NHR claim 1 , an optionally substituted Calkoxy claim 1 , and an optionally ...

Подробнее
25-04-2013 дата публикации

Substituted Tetracycline Compounds

Номер: US20130102779A1
Автор: Abato Paul
Принадлежит: PARATEK PHARMACEUTICALS, INC.

The present invention pertains to tetracycline compounds of formula (VIIa): 2. The tetracycline compound of claim 1 , wherein Ris oxazolyl.3. The tetracycline compound of claim 2 , wherein oxazolyl is substituted with methyl or isopropyl.4. The tetracycline compound of claim 1 , wherein Ris oxadiazolyl.5. The tetracycline compound of claim 4 , wherein oxadiazolyl is substituted with alkyl.6. The tetracycline compound of claim 1 , wherein Ris isoxazolyl.7. The tetracycline compound of claim 1 , wherein Ris pyrazolyl.8. The tetracycline compound of claim 7 , wherein Ris methylpyrazolyl.9. The tetracycline compound of claim 1 , wherein Ris —CONRR claim 1 , in which Ris hydrogen and Ris hydroxyl claim 1 , hydroyxalkyl claim 1 , alkoxy claim 1 , phenyl claim 1 , or alkyl.10. The tetracycline compound of claim 1 , wherein Ris wherein Ris —CONRR claim 1 , in which Ris alkyl and Ris alkyl or hydroxyl.11. The tetracycline compound of claim 1 , wherein Ris dialkylamino.12. The tetracycline compound of claim 11 , wherein Ris dimethylamino.13. The tetracycline compound of claim 1 , wherein each of R claim 1 , R claim 1 , R claim 1 , and R is hydrogen.14. The tetracycline compound of claim 13 , wherein Ris dialkylamino.15. The tetracycline compound of claim 14 , wherein Ris dimethylamino.19. A pharmaceutical composition comprising a tetracycline compound of and a pharmaceutically acceptable carrier.20. A method for treating a tetracycline responsive state in a subject claim 1 , comprising administering to said subject an effective amount of a tetracycline compound of claim 1 , such that said subject is treated. This application is a divisional application of U.S. Ser. No. 11/963,540, filed on Dec. 21, 2007 and issued as U.S. Pat. No. 8,318,706 on Nov. 27, 2012, which claims priority to U.S. Provisional Patent Application No. 60/876,313, filed on Dec. 21, 2006 and U.S. Provisional Patent Application No. 60/943,003, filed Jun. 8, 2007. The contents of the foregoing applications ...

Подробнее
02-05-2013 дата публикации

HAPTEN CONJUGATES FOR TARGET DETECTION

Номер: US20130109019A1
Принадлежит:

Embodiments of hapten conjugates including a hapten, an optional linker, and a peroxidase-activatable aryl moiety are disclosed. In some embodiments, the peroxidase-activatable aryl moiety is tyramine or a tyramine derivative. Embodiments of methods for making and using the hapten conjugates also are disclosed. In particular embodiments, the hapten conjugates are used in a signal amplification assay. In certain embodiments, the hapten is an oxazole, a pyrazole, a thiazole, a benzofurazan, a triterpene, a urea, a thiourea other than a rhodamine thiourea, a nitroaryl other than dinitrophenyl or trinitrophenyl, a rotenoid, a cyclolignan, a heterobiaryl, an azoaryl, a benzodiazepine, or 7-diethylamino-3-carboxycoumarin. The hapten is coupled to the peroxidase-activatable aryl moiety directly or indirectly via a linker. In certain embodiments, the hapten conjugates are used in multiplexed assays. 1. A hapten conjugate , comprising:a hapten selected from an oxazole, a pyrazole, a thiazole, a benzofurazan, a triterpene, a urea, a thiourea other than a rhodamine thiourea, a nitroaryl other than dinitrophenyl or trinitrophenyl, a rotenoid, a cyclolignan, a heterobiaryl, an azoaryl, a benzodiazepine, 2,3,6,7-tetrahydro-11-oxo-1H,5H,11H-[1]benzopyrano[6,7,8-ij]quinolizine-10-carboxylic acid, or 7-diethylamino-3-carboxycoumarin;a linker; anda tyramine or a tyramine derivative.2. (canceled)6. (canceled)811.-. (canceled)1332.-. (canceled)33. A method , comprising:(a) immobilizing a first peroxidase on a first target in a sample, wherein the first peroxidase is capable of reacting with a peroxidase-activatable aryl moiety;(b) contacting the sample with a solution comprising a first hapten conjugate, the first hapten conjugate comprising a first hapten selected from an oxazole, a pyrazole, a thiazole, a benzofurazan, a triterpene, a urea, a thiourea other than a rhodamine thiourea, a nitroaryl other than dinitrophenyl or trinitrophenyl, a rotenoid, a cyclolignan, a heterobiaryl, an ...

Подробнее
02-05-2013 дата публикации

C7-Fluoro Substituted Tetracycline Compounds

Номер: US20130109657A1
Принадлежит: Tetraphase Pharmaceuticals Inc

The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

Подробнее
02-05-2013 дата публикации

Small Molecule Inhibitors of Functions of the HIV-1 Matrix Protein

Номер: US20130109698A1
Автор: Simon Cocklin
Принадлежит: Simon Cocklin

The present invention includes a method of inhibiting, suppressing or preventing retroviral infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising one or more of the compounds of the invention.

Подробнее
16-05-2013 дата публикации

HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF

Номер: US20130121919A1

The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject. 8. A method for screening compounds of Formula (I) , Formula (II) , Formula (III) , or Formula (V) to treat conditions associated with accumulated amyloid-beta peptide deposits , the method comprising:a) administering a HAT Activator compound of Formula (I), Formula (II), Formula (III), or Formula (V) to an animal model of amyloid-beta peptide deposit accumulation; andb) selecting a HAT Activator compound of Formula (I), Formula (II), Formula (III), or Formula (V) that can modulate histone acetylation after administration of the HAT Activator compound in an animal model of amyloid-beta peptide deposit accumulation.9. A method for identifying a histone acetyltransferase (HAT) activator compound of Formula (I) , Formula (II) , Formula (III) , or Formula (V) to treat conditions associated with accumulated amyloid-beta peptide deposits , wherein the method comprises selecting a HAT Activator compound of Formula (I) , Formula (II) , Formula (III) , or Formula (V) having one or more of the following features:{'sub': '50', 'a) the ECof the compound is no more than about 1000 nM;'}b) the histone acetylation activity in vitro targets histone protein H2, H3, and/or H4; andc) the compound penetrates the blood brain barrier; or a combination thereof.10. The method of claim 9 , wherein the compound has a molecular mass less than about 500 Da claim 9 , has a polar surface area less than about 90 Å claim 9 , has less than 8 hydrogen bonds claim 9 , or a combination thereof claim 9 , in order to penetrate the blood brain barrier.12. The method of claim 11 , wherein the subject ...

Подробнее
16-05-2013 дата публикации

NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF

Номер: US20130123338A1
Принадлежит: Protiva Biotherapeutics, Inc.

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. 2. The cationic lipid of claim 1 , wherein Rand Rare independently selected from the group consisting of a methyl group and an ethyl group.3. The cationic lipid of claim 1 , wherein Rand Rare both methyl groups.4. The cationic lipid of claim 1 , wherein Rand Rare joined to form an optionally substituted heterocyclic ring having from 2 to 5 carbon atoms and from 1 to 3 heteroatoms selected from the group consisting of nitrogen (N) claim 1 , oxygen (O) claim 1 , sulfur (S) claim 1 , and combinations thereof.5. The cationic lipid of claim 1 , wherein X is O claim 1 , C(O)O claim 1 , C(O)N(R) claim 1 , N(R)C(O)O claim 1 , or C(O)S.6. The cationic lipid of claim 1 , wherein Ris selected from the group consisting of hydrogen (H) and an optionally substituted methyl group claim 1 , ethyl group claim 1 , or C-Calkyl claim 1 , alkenyl claim 1 , or alkynyl group.7. The cationic lipid of claim 1 , wherein X is an optionally substituted heterocyclic ring having from 2 to 5 carbon atoms and from 1 to 3 heteroatoms selected from the group consisting of nitrogen (N) claim 1 , oxygen (O) claim 1 , sulfur (S) claim 1 , and combinations thereof.8. The cationic lipid of claim 1 , wherein Y is (CH)and n is 0 claim 1 , 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 claim 1 , 5 claim 1 , or 6.9. The cationic lipid of claim 8 , wherein n is 2 claim 8 , ...

Подробнее
16-05-2013 дата публикации

MODULATOR

Номер: US20130123356A1
Принадлежит: UNIVERSITY COLLEGE LONDON

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, 2. A compound according to wherein Y is selected from CN claim 1 , OH claim 1 , COOR claim 1 , SONRR claim 1 , CONRR claim 1 , where each of Rand Ris independently H or a hydrocarbyl group.3. A compound according to wherein each of R claim 1 , R claim 1 , Rand Ris independently H claim 1 , an alkyl group claim 1 , an aryl group claim 1 , or a cycloalkyl group claim 1 , each of which may be optionally substituted.4. A compound according to wherein Y is selected from OH claim 1 , CN claim 1 , COOR claim 1 , CONRR claim 1 , where each of Rand Ris independently H or an optionally substituted alkyl group.5. A compound according to wherein Y is selected from OH claim 1 , CN claim 1 , COOMe claim 1 , COOH claim 1 , CONH claim 1 , CONHMe and CONMe.6. A compound according to wherein X—Y is selected from{'br': None, 'sub': 2', 'p, '—C≡C—(CH)—Y'}{'br': None, 'sup': 5', '6, 'sub': 2', 'q, '—C(R)═C(R)—(CH)—Y; and'}{'br': None, 'i': 'r', '—C(R5)(R6)C(R8)-(CH2)-Y;'}{'sup': 5', '6', '7', '8, 'wherein each of R, R, R, and Ris independently H or alkyl, and each of p, q and r is independently 2, 3, or 4.'}7. A compound according to wherein X—Y is selected from{'br': None, 'sub': 2', 'p, '—C≡C—(CH)—Y; and'}{'br': None, 'sub': 2', 'q, '—CH═CH—(CH)—Y;'}wherein each of p and q is independently 2, 3 or 4.8. A compound according to wherein X—Y is{'br': None, 'sup': 5', '6, 'sub': 2', 'q, 'i': 'q', 'cis-C(R)═C(R)—(CH)—Y and is 2, 3 or 4.'}9. A compound according to wherein X—Y is —C(Me)-CH—(CH)—Y and r is 2 claim 1 , 3 or 4.10. A compound according to wherein A is phenyl.11. A compound according to wherein Z is ORor NRRand each of Rand Ris independently H claim 1 , an alkyl or a cycloalkyl group claim 1 , each of which may be optionally substituted by one or more OH or halogen groups.12. A compound according to wherein Z is selected from OH claim 1 , OEt claim 1 , NHCHCHF claim 1 , NH- ...

Подробнее
16-05-2013 дата публикации

Beta-Ketocarbonylquat Compounds and Process for the Preparation thereof

Номер: US20130123535A1
Автор: Herzig Christian
Принадлежит: Wacker Chemie AG

β-ketocarbonylquats contain at least one quaternary ammonium salt group, and may be prepared by the reaction of an alkyl ketene dimer with a tertiary amine group-containing compound also containing a protic group, followed by quaternization. 18.-. (canceled)9. A β-ketocarbonylquat comprising one or more β-ketocarbonyl groups of general formula{'br': None, 'sub': '2', 'R—CH—(C═O)—CHR—(C═O)—\u2003\u2003(I)'}and one or more quaternary ammonium groups, whereinR each, independently, is an aliphatic hydrocarbon radical of 6 to 28 carbon atoms, with the proviso that the β-ketocarbonyl group of formula (I) is bonded to a radical Y, wherein{'sup': '1', 'Y is a divalent radical of the formula —O—, —NH—, —NR—, and'}{'sup': '1', 'Ris a monovalent hydrocarbon radical of 1 to 30 carbon atoms.'}10. The β-ketocarbonylquat of claim 9 , wherein the aliphatic hydrocarbon radical R contains 10-26 carbon atoms.11. The β-ketocarbonylquat of claim 9 , wherein the aliphatic hydrocarbon radical R contains 12-20 carbon atoms.12. The β-ketocarbonylquat of claim 9 , wherein Y is —NH— claim 9 , —NR— claim 9 , or a trivalent radical of the formula =N—.13. The β-ketocarbonylquat of claim 9 , wherein Rcontains 1-18 carbon atoms.14. The β-ketocarbonylquat of claim 9 , having the formula{'br': None, 'sup': 3', '4', '5', '(+)', '2', '(−), 'sub': 'a', '[RRRN—R—]Y—Z X\u2003\u2003(II)'}whereina is 1 or 2, with the proviso that when a is 1, Y is a divalent radical and when a is 2, Y is a trivalent radical,{'sup': '1', 'Y is a divalent radical of formula —O—, —NH—, —NR—, or a trivalent radical of formula =N—,'}{'sup': '(−)', 'Xis a counter-ion to the positive charge on the quaternary nitrogen atom,'} {'br': None, 'sub': '2', 'R—CH—(C═O)—CHR—(C═O)—\u2003\u2003(I)'}, 'Z is a β-ketocarbonyl group of the formula'}R each, independently is an aliphatic hydrocarbon radical of 6 to 28 carbon atoms,{'sup': '1', 'Ris a monovalent hydrocarbon radical of 1 to 30 carbon atoms,'}{'sup': '2', 'sub': 1', '18, 'Ris a ...

Подробнее
16-05-2013 дата публикации

Imaging Agents

Номер: US20130123618A1
Автор: Mark M. Goodman
Принадлежит: EMORY UNIVERSITY

This invention provides amino acid derivatives useful in detecting and evaluating brain and body tumors, including (1S,2S) anti-2-[ 18 F]FACPC and (1R,2R) anti-2-[ 18 F]FACPC.

Подробнее
23-05-2013 дата публикации

NOVEL CATIONIC AMPHIPHILES WITH MANNOSE-MIMICKING HEAD-GROUPS AND A PROCESS FOR THE PREPARATION THEREOF

Номер: US20130129758A1

The present invention discloses novel cationic amphiphiles containing mannose-mimicking shikimic and quinic acid head-groups and a process for preparing cationic amphiphiles with mannose-mimicking polar head-groups such as, shikimic and quinic acids. The findings described herein also demonstrate that compounds of the present invention can target model DNA vaccines to antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs), via mannose receptors expressed on the cell surface of APCs. The cationic amphiphiles disclosed herein show enhanced cellular and humoral immune response compared to their mannosyl counterpart in dendritic cell (DC, the most professional APC) based genetic immunization in mice. Cationic amphiphiles with mannose-mimicking quinic and shikimic acid head-groups described in the present invention are likely to find future applications in the field of genetic immunization. 3. The cationic amphiphile of claim 1 , wherein lipophilic Rand Rmoiety is selected from the group consisting of saturated C-Calkyl groups and unsaturated C-Calkenyl groups containing 1 claim 1 , 2 or 3 double bonds.5. The process of claim 4 , wherein saturated or unsaturated aliphatic hydrocarbon chains of said amine have 8-22 carbon atoms.6. The process of claim 4 , wherein the polar aprotic solvent used in step (a) is selected from the group consisting of dichloro methane (DCM) claim 4 , dimethyl formamide (DMF) claim 4 , dimethylsulfoxide claim 4 , pyridine claim 4 , and triethyl amine.7. The process of claim 4 , wherein quaternization of the intermediate hydrophobic amide obtained in step (a) is carried out at a temperature between 25-30° C.8. The process of claim 4 , wherein the organic solvent used as polar eluent in step (c) is selected from the group consisting of methanol claim 4 , ethanol claim 4 , chloroform claim 4 , dichloro methane and ethyl acetate.9. The process of claim 4 , wherein the halide ion exchange resins used in step (c) is selected ...

Подробнее
23-05-2013 дата публикации

METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS

Номер: US20130129785A1
Принадлежит: ALNYLAM PHARMACEUTICALS, INC

A lipid particle can include a cationic lipid. Synthesis of the cationic lipid can include a ylide-based reaction, such as a Wittig reaction or sulfur ylide reaction. In some cases, the synthesis can also include a Michael addition or a related addition reaction. 2. The compound of claim 1 , wherein X are Y are alkyl.3. The compound of claim 3 , wherein X and Y are both methyl.4. The compound of claim 1 , wherein Lis a linear alkylene unit.5. The compound of claim 1 , wherein Lis a linear alkylene unit.6. The compound of claim 5 , wherein Lcontains one or more double bonds and one or more cycloalkylene groups.7. The compound of claim 1 , wherein Rand Rare each claim 1 , independently claim 1 , C-Calkyl or C-Calkenyl.8. The compound of claim 7 , wherein one of Rand Ris a linear C-Calkyl or C-Calkenyl group and the other of Rand Ris a branched C-Calkyl or C-Calkenyl group.9. The compound of claim 1 , wherein Z is —C(O)O— claim 1 , —C(O)N(R)— claim 1 , —O(CO)N(R) claim 1 , —C(O)N(R)C(O)O— claim 1 , or —N(R)C(O)N(R)—.10. The compound of claim 1 , wherein Ris H or alkyl.11. The compound of claim 1 , wherein{'sub': 1', '4, 'X and Y are each, independently, C-Calkyl;'}{'sup': 1', '2, 'sub': 2', '10, 'Land Lare each, independently, an C-Clinear or branched alkylene linking unit, which may optionally contain one or more double bonds and further may optionally be interrupted by one or more heteroatoms and/or one or more cycloalkylene groups;'}{'sub': 1', '2', '10', '30, 'Rand Rare each, independently, a C-Caliphatic group, which may optionally contain one or more double bonds, and may optionally be interrupted by one or more heteroatoms and/or one or more cycloalkylene groups;'}{'sup': 3', '3', '3', '3', '3', '3', '3', '3, 'Z is —C(O)O—, —OC(O)—, —C(O)N(R)—, —N(R)C(O)—, —O(CO)N(R), —N(R)C(O)O—, —C(O)N(R)C(O)O—, —OC(O)N(R)C(O)— or —N(R)C(O)N(R)—;'}{'sup': '3', 'sub': 1', '4, 'each occurrence of Ris independently H or C-Calkyl; and'}{'img': [{'@id': 'CUSTOM-CHARACTER-00003', '@ ...

Подробнее
23-05-2013 дата публикации

O-CYCLOPROPYLCYCLOHEXYL-CARBOXANILIDES AND THEIR USE AS FUNGICIDES

Номер: US20130131124A1
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to O-CYCLOPROPYLCYCLOHEXYL-CARBOXANILIDES derivatives of formula (I); their process of preparation, their use as fungicide, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. 2. A compound of formula (I) as claimed in claim 1 , wherein{'sup': 1', '2, 'Rand Rare, independently, hydrogen or fluoro;'}{'sup': '3', 'sub': 2-6', '3-8, 'Ris Calkyl, optionally substituted Ccycloalkyl, phenyl, thienyl or furyl;'}A represents one of the radicals A1, A2, A3, A4, A5, A6, A9, A10, A11, A12 or A17;{'sup': '18', 'sub': 1', '2', '1', '2, 'Rrepresents hydrogen, cyano, fluorine, chlorine, bromine, iodine, methyl, ethyl, isopropyl, methoxy, ethoxy, methylthio, ethylthio, cyclopropyl, C-Chaloalkyl C-C-haloalkoxy having in each case 1 to 5 fluorine, chlorine and/or bromine atoms, trifluoromethylthio, difluoromethylthio, aminocarbonyl, aminocarbonylmethyl or aminocarbonylethyl;'}{'sup': '19', 'Rrepresents hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, methoxy, ethoxy, methylthio or ethylthio;'}{'sup': '20', 'sub': 1', '2, 'Rrepresents hydrogen, methyl, ethyl, n-propyl, isopropyl, C-C-haloalkyl having 1 to 5 fluorine, chlorine and/or bromine atoms, hydroxymethyl, hydroxyethyl, cyclopropyl, cyclopentyl, cyclohexyl or phenyl.'}{'sup': 21', '22, 'sub': 1', '2, 'Rand Rindependently of one another represent hydrogen, fluorine, chlorine, bromine, methyl, ethyl or C-C-haloalkyl having 1 to 5 fluorine, chlorine and/or bromine atoms;'}{'sup': '23', 'sub': 1', '2', '1', '2, 'Rrepresents fluorine, chlorine, bromine, cyano, methyl, ethyl, C-C-haloalkyl or C-C-haloalkoxy having in each case 1 to 5 fluorine, chlorine and/or bromine atoms;'}{'sup': 24', '25, 'sub': 1', '2, 'Rand Rindependently of one another represent hydrogen, fluorine, chlorine, bromine, methyl, ethyl or C-C-haloalkyl having 1 to 5 fluorine, chlorine and/or bromine atoms;'}{'sup ...

Подробнее
23-05-2013 дата публикации

DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO

Номер: US20130131310A1
Принадлежит:

The present invention relates to methods for synthesizing compounds of formula I or pharmaceutically acceptable salts thereof: (I) wherein each of X, Alk, and W are as defined and described herein. 3. The method of claim 2 , wherein each occurrence of X is the same ligand.4. The method of claim 2 , wherein LGis —OSu.5. The method of claim 2 , wherein the compound of formula II is selected from those depicted in .1523-. (canceled) International Application No. PCT/US2010/22268 describes conjugate-based systems, methods for their preparation, and use of these conjugates, e.g., as therapeutics. Alternative synthetic methods for drug-ligand conjugates are desired.As described herein, the present invention provides methods for preparing drug-ligand conjugates capable of controlling the pharmacokinetic (PK) and/or pharmacodynamic (PD) profiles of a drug such as insulin in a manner that is responsive to the systemic concentrations of a saccharide such as glucose. Such conjugates include those of formula I:The present invention also provides synthetic intermediates useful for preparing such conjugates. In certain embodiments, an exemplary useful intermediate in the preparation of a drug-ligand conjugate is a compound of formula A:wherein X, Alk, and LGare as defined and described in embodiments herein.The present invention also provides methods for preparing conjugates that include a detectable label instead of a drug as W.Definitions of specific functional groups, chemical terms, and general terms used throughout the specification are described in more detail below. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, ...

Подробнее
30-05-2013 дата публикации

4-carboxybenzylamino derivatives as histone deacetylase inhibitors

Номер: US20130137690A1
Принадлежит: Individual

The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the 4-carboxybenzylamino derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the 4-carboxybenzylamino derivatives in vivo.

Подробнее
13-06-2013 дата публикации

OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE IN TREATING CANCERS

Номер: US20130150442A1
Автор: Ahn Jung-Mo, RAJ Ganesh

The present invention includes bis- and tris-benzamide compounds that block AR signaling and have activity against prostate cancer. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided. 2. The compound of claim 1 , wherein X is —NO.3. The compound of claim 1 , wherein Y is —C(O)NH.4. The compound of claim 2 , wherein A claim 2 , A′ and A″ are each O.5. The compound of claim 2 , wherein R claim 2 , Rand Rare independently Calkyl claim 2 , Chydroxyalkyl claim 2 , Calkenyl or C-Carylalkyl.6. The compound of claim 4 , wherein R claim 4 , Rand Rare independently Calkyl claim 4 , Chydroxyalkyl claim 4 , Calkenyl or C-Carylalkyl.7. The compound of claim 2 , wherein R claim 2 , Rand Rare independently Calkyl or Cto hydroxyalkyl.8. The compound of claim 4 , wherein R claim 4 , Rand Rare independently Calkyl or Cto hydroxyalkyl.9. The compound of claim 1 , wherein Y is COOCH.10. The compound of claim 1 , wherein A claim 1 , A′ and A″ are each NH.11. The compound of claim 9 , wherein A claim 9 , A′ and A″ are each NH.12. The compound of claim 9 , wherein R claim 9 , Rand Rare independently Calkyl claim 9 , Chydroxyalkyl claim 9 , Calkenyl or C-Carylalkyl.13. The compound of claim 11 , wherein R claim 11 , Rand Rare independently Calkyl or Chydroxyalkyl.14. The compound of claim 1 , wherein X is —NOand Y is —C(O)NH.15. The compound of claim 14 , wherein A claim 14 , A′ and A″ are each O.16. The compound of claim 14 , wherein R claim 14 , Rand Rare independently Calkyl claim 14 , Chydroxyalkyl claim 14 , Calkenyl or C-Carylalkyl.17. The compound of claim 15 , wherein R claim 15 , Rand Rare independently Calkyl claim 15 , Chydroxyalkyl claim 15 , Calkenyl or C-Carylalkyl.18. The compound of claim 14 , wherein R claim 14 , Rand Rare independently Calkyl or Chydroxyalkyl.19. The compound of claim 15 , wherein R claim 15 , Rand Rare independently Calkyl or Chydroxyalkyl.2120. A method of inhibiting a prostate tumor cell in a subject ...

Подробнее
27-06-2013 дата публикации

BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Номер: US20130165443A1
Принадлежит:

Compounds of the formula I: 2. The compound of claim 1 , wherein R claim 1 , Rand Rare hydrogen.3. The compound of claim 2 , wherein Ris phenyl substituted at the 4-position with methyl or halo and optionally substituted at the 2-position with halo.4. The compound of claim 2 , wherein Ris 4-methyl-phenyl.5. The compound of claim 2 , wherein Ris pyridin 2-yl substituted with methyl or halo at the 5-position.6. The compound of claim 2 , wherein Ris 5-methyl-pyridin-2-yl.8. The compound of claim 7 , wherein Ris hydrogen.9. The compound of claim 7 , wherein Ris methyl.10. The compound of claim 7 , wherein Ris: Calkyl; Calkyloxy-Calkyl; hydroxy-Calkyl; Calkylsulfanyl-Calkyl; Calkylsulfonyl-Calkyl; amino-Calkyl; N—Calkyl-amino-Calkyl; N claim 7 ,N-di-Calkyl-amino-Calkyl; Ccycloalkyl; optionally substituted phenyl; heteroaryl claim 7 , or heterocyclyl-Calkyl.11. The compound of claim 7 , wherein Ris: Calkyloxy-Calkyl; hydroxy-Calkyl; heteroaryl claim 7 , or heterocyclyl-Calkyl.12. The compound of claim 7 , wherein Ris methoxymethyl.13. The compound of claim 7 , wherein Ris hydroxymethyl.14. The compound of claim 7 , wherein Ris heteroaryl selected from pyridinyl claim 7 , pyrimidinyl claim 7 , or pyrazinyl claim 7 , each of which may be optionally substituted once or twice with methyl.15. The compound of claim 7 , wherein Ris hydroxymethyl claim 7 , methoxymethyl claim 7 , pyrazin-2-yl or 5-methyl-pyrazin-2-yl.16. The compound of claim 7 , wherein Ris Calkyl claim 7 , Ccycloalkyl or Ccycloalkyl-Calkyl.17. The compound of claim 7 , wherein Ris isopropyl claim 7 , isobutyl or tert butyl.18. The compound of claim 1 , wherein said compound is selected from:4-Methyl-thiophene-2-carboxylic acid [5-(2-methoxy-1-methyl-ethylcarbamoyl)-4′-methyl-biphenyl-3-yl]-amide;5-Methyl-thiophene-2-carboxylic acid [5-(2-methoxy-1-methyl-ethylcarbamoyl)-4′-methyl-biphenyl-3-yl]-amide;Furan-2-carboxylic acid [5-(2-methoxy-1-methyl-ethylcarbamoyl)-4′-methyl-biphenyl-3-yl]-amide;Thiophene-2- ...

Подробнее
04-07-2013 дата публикации

Cysteine protease inhibitors

Номер: US20130172232A1
Принадлежит: Medivir UK Ltd

Compounds of the formula I wherein R 2a and R 2b are independently H, halo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl or C 1 -C 4 alkoxy, or R 2a and R 2b together with the carbon atom to which they are attached form a C 3 -C 6 cycloalkyl; R 3 is a C 5 -C 10 alkyl, optionally substituted with 1-3 substituents independently selected from halo, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy; or R 3 is a C 2 -C 4 alkyl chain with at least 2 chloro or 3 fluoro substituents; or R 3 is C 3 -C 7 cycloalkylmethyl, optionally substituted with 1-3 substituents independently selected from C 1 -C 4 alkyl, halo, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy; R 4 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino or; R 4 is Het or Carbocyclyl, either of which is optionally substituted with 1-3 substituents R 4 is Het, carbocyclyl, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy; n is 1, 2 or 3; for the use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

Подробнее
11-07-2013 дата публикации

Cannabinoid receptor modulators

Номер: US20130178457A1
Принадлежит: Lupin Ltd

Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I).

Подробнее
18-07-2013 дата публикации

Labeling Agent and Methods for Simultaneous Sequencing and Quantification of Multiple Peptides and Proteins Using the Same

Номер: US20130183704A1
Принадлежит: POSTECH ACADEMY-INDUSTRY FOUNDATION

The present invention provides a compound that can utilize hydrogen isotope and, at the same time, can quantify multiplexed samples at one time, as well as decreasing the cost for synthesis of the labeling agent. In addition, the present invention provides a novel method for quantitatively analyzing protein and peptide analytes having different quantities form each other using the labeling agent, wherein y-type fragment ions having a high mass which comprises the analyte remained after coupling the labeling agent with the analyte and then removing a part of the labeling agent through tandem mass spectrometry are utilized to conduct the quantitative analysis. 3. The compound according to claim 2 , characterized in that Ris octyl; and Ris heptyl.5. The compound according to claim 1 , characterized in that{'sub': 1', '2, 'Rand Rare'}{'sub': 3', '6', '4', '2', '3', '6', '4', '2', '2, 'CHC≡CCHCHand CDC≡CCHCDCH, respectively;'}{'sub': 3', '6', '4', '2', '3', '6', '4', '2', '2, 'CHC≡CCHCDand CDC≡CCHCHCH, respectively;'}{'sub': 3', '6', '4', '2', '3', '6', '4', '2', '2, 'CDC≡CCHCHand CHC≡CCHCDCH, respectively; or'}{'sub': 3', '6', '4', '2', '3', '6', '4', '2', '2, 'CDC≡CCHCDand CHC≡CCHCHCH, respectively.'}6. The compound according to claim 1 , characterized in that Ris a side chain of any one amino acid residue selected from the group consisting of glycine claim 1 , alanine claim 1 , serine claim 1 , valine claim 1 , leucine claim 1 , isoleucine claim 1 , methionine claim 1 , glutamine claim 1 , asparagine claim 1 , cysteine claim 1 , histidine claim 1 , phenylalanine claim 1 , arginine claim 1 , tyrosine and tryptophan.7. The compound according to claim 1 , characterized in that Ris hydroxy claim 1 , succinimid-N-oxy claim 1 , 3-sulfosuccinimid-N-oxy claim 1 , benzotriazol-1-yl-oxy claim 1 , pentahalobenzyloxy claim 1 , 4-nitrophenoxy or 2-nitrophenoxy.8. The compound according to claim 1 , characterized in that said compound is any one selected from the group consisting ...

Подробнее
18-07-2013 дата публикации

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Номер: US20130184222A1
Принадлежит: AGIOS PHARMACEUTICALS, INC

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here. 2. The compound of claim 1 , wherein Ris 3-fluorophenyl.3. The compound of or claim 1 , wherein:{'sup': '1', 'Ris selected from cyclohexyl, cyclopentyl, cycloheptyl, 3,3-difluorocyclobutyl, 4,4,-difluorocyclohexyl, and bicyclo[2.2.1]heptanyl; and'}{'sup': '4', 'Ris selected from 1-(methylmethoxycarbonylamino)ethyl, 1,2,3,4-tetrahydroquinolin-1-yl, 1-ethoxycarbonylpiperidin-2-yl, 1-ethoxycarbonylpyrrolidin-2-yl, 1H-benzimidazol-1-ylmethyl, 1H-indazol-3-ylmethyl, indolin-1-ylmethyl, 1H-indol-3-ylmethyl, 1H-indol-5-ylmethyl, 1H-pyrrolo[2,3-b]pyridine-3-ylmethyl, 1H-pyrrolo[3,2-b]pyridin-3-ylmethyl, 1-methoxycarbonylpiperidin-2-yl, 1-methoxycarbonylpyrrolidin-2-yl, 2-fluoropyridin-3-ylaminomethyl, 2-imino-4-fluoropyridin-1-ylmethyl, 2-methoxyphenylaminomethyl, 2-methyl-1H-benzimidazol-1-ylmethyl, 2-methylimidazol-1-ylmethyl, 2-trifluoromethyl-1H-imidazol-1-yl, 3-cyanophenylaminomethyl, 3-fluoropyridin-2-ylaminomethyl, 3-methoxyphenylaminomethyl, 4-(1,3,4-oxadiazole-2-yl)phenylaminomethyl, 4-(dimethylaminocarbonyloxy)phenylmethyl, 4,5-dichloroimidazol-1-ylmethyl, 4-cyanophenylaminomethyl, 4-fluorophenylaminomethyl, 4-fluoropyridin-2-ylaminomethyl, 4-hydroxyphenylmethyl, 4-methoxycarbonylmorpholin-3-yl, 4-methoxycarbonylpiperazin-1-ylmethyl, 4-methoxyphenylaminomethyl, 4-methylcarbonyloxyphenylmethyl, 5-fluoropyridin-2-aminomethyl, 5-fluoropyridin-2-oxymethyl, 6-fluoropyridin-3-ylaminomethyl, benzomorpholin-4-ylmethyl, methoxycarbonylaminomethyl, methylmethoxycarbonylaminomethyl, methylphenylaminomethyl, phenylaminomethyl, pyridin-2-oxymethyl, pyridin-2-ylaminomethyl, pyridin-2-yloxymethyl, pyridin-3-oxymethyl, pyridin-3-ylmethyl, pyridin-4-ylmethyl, thiazol-4-ylmethyl, and thien-2-ylmethyl.'}4. The compound of claim 1 , wherein the compound is selected from any one of Compound numbers 104 claim ...

Подробнее
18-07-2013 дата публикации

ACID ADDITION SALT OF A NORTRIPTYLINE-GABA CONJUGATE AND A PROCESS OF PREPARING SAME

Номер: US20130184347A1
Принадлежит:

An acid addition salt of a nortriptyline-GABA conjugate, a novel crystalline form of a fumaric acid addition salt of a nortriptyline-GABA conjugate, and processes of preparing the forgoing are disclosed. Uses of the above-indicated forms of a nortriptyline-GABA conjugate in the treatment of CNS disorders, and in the treatment of pain in particular, are also disclosed. Further disclosed in a large-scale process of preparing a nortriptyline-GABA conjugate. 149-. (canceled)50. A fumaric acid addition salt of nortriptyline-4-aminobutyrate.51. A crystalline form of a fumaric acid addition salt of nortriptyline-4-aminobutyrate , characterized by at least one of:{'figref': {'@idref': 'DRAWINGS', 'FIG. 3'}, '(a) an X-Ray Powder Diffraction (XRPD) pattern exhibiting at least four of the peaks shown in ;'}{'figref': {'@idref': 'DRAWINGS', 'FIG. 1'}, '(b) an infrared spectrum exhibiting at least three of the absorption peaks shown in ; and'}(c) a Differential Scanning calorimetry (DSC) exhibiting an endothermic peak maximum that ranges from 155° C. to 160° C.52. The crystalline form of nortriptyline-4-aminobutyrate fumarate of claim 51 , characterized by an X-Ray Powder Diffraction (XRPD) pattern exhibiting at least six of the peaks shown in .53. The crystalline form of nortriptyline-4-aminobutyrate fumarate of claim 51 , characterized by an X-Ray Powder Diffraction (XRPD) pattern exhibiting at least seven of the peaks shown in .54. The crystalline form of nortriptyline-4-aminobutyrate fumarate of claim 51 , characterized by an X-Ray Powder Diffraction (XRPD) pattern substantially identical to the XRPD pattern shown in .55. The crystalline form of nortriptyline-4-aminobutyrate fumarate of claim 51 , characterized by an infrared spectrum exhibiting at least five of the absorption peaks shown in .56. The crystalline form of a fumaric acid addition salt of nortriptyline-4-aminobutyrate of claim 51 , characterized by an infrared spectrum exhibiting absorption peaks substantially ...

Подробнее
25-07-2013 дата публикации

DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO

Номер: US20130190475A1
Принадлежит: SMARTCELLS, INC.

The present invention relates to methods for synthesizing compounds of formula I or pharmaceutically acceptable salts thereof: I wherein each of X, Alk, Alk, and W are as defined and described herein. 3: The method of claim 2 , wherein each occurrence of X is the same ligand.4: The method of claim 2 , wherein LGis —OSu.5. (canceled)2231-. (canceled) International Application No. PCT/US2010/22268 describes conjugate-based systems, methods for their preparation, and use of these conjugates, e.g., as therapeutics. Alternative synthetic methods for drug-ligand conjugates are desired.As described herein, the present invention provides methods for preparing drug-ligand conjugates capable of controlling the pharmacokinetic (PK) and/or pharmacodynamic (PD) profiles of a drug such as insulin in a manner that is responsive to the systemic concentrations of a saccharide such as glucose. Such conjugates include those of formula I:The present invention also provides synthetic intermediates useful for preparing such conjugates. In certain embodiments, an exemplary useful intermediate in the preparation of a drug-ligand conjugate is a conjugate of formula A:wherein X, Alk, Alk, and LGare as defined and described in embodiments herein.The present invention also provides methods for preparing conjugates that include a detectable label instead of a drug as W.Definitions of specific functional groups, chemical terms, and general terms used throughout the specification are described in more detail below. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March ...

Подробнее
25-07-2013 дата публикации

Process for the preparation of amino acid derivatives

Номер: US20130190533A1
Принадлежит: UCB PHARMA GMBH

The present invention relates to a process of manufacture of compounds of formula (B) wherein R 1 , R 2 and R 3 are as defined for compounds of formula (A), which process comprises hydrogenation of compounds of general formula (A). In particular, the present invention relates to an improved process for the manufacture of Lacosamide (LCM), (R)-2-acetamido-N-benzyl-3-methoxypropion-amide (B1), which is useful as an anticonvulsive drug.

Подробнее
01-08-2013 дата публикации

GENES FOR BIOSYNTHESIS OF TETRACYCLINE COMPOUNDS AND USES THEREOF

Номер: US20130196953A1
Принадлежит: UNIVERZA V LJUBLJANI

The invention relates to tetracycline products produced by genetically engineered cells, and to therapeutic methods using such tetracyclines. The present invention is based on the cloning and heterologous expression of genes encoding the chelocardin biosynthetic pathway. 3. Use of a compound of for the treatment of bacterial or fungal infections claim 1 , treatment of malaria claim 1 , a neurodegenerative disease claim 1 , Parkinson's disease claim 1 , Huntington's claim 1 , disease claim 1 , periodontitis claim 1 , an autoimmune condition claim 1 , multiple sclerosis claim 1 , atherosclerosis claim 1 , rheumatoid arthritis claim 1 , osteoporosis claim 1 , tumour invasion claim 1 , cancer and inflammatory states.4. Use of a compound of for the treatment of bacterial or fungal infections.5. Use of a compound of for the treatment of bacterial or fungal infections claim 2 , treatment of malaria claim 2 , a neurodegenerative disease claim 2 , Parkinson's disease claim 2 , Huntington's claim 2 , disease claim 2 , periodontitis claim 2 , an autoimmune condition claim 2 , multiple sclerosis claim 2 , atherosclerosis claim 2 , rheumatoid arthritis claim 2 , osteoporosis claim 2 , tumour invasion claim 2 , cancer and inflammatory states.6. Use of a compound of for the treatment of bacterial or fungal infections. This application is a divisional of U.S. patent application Ser. No. 12/536,622 filed Aug. 6, 2009, now U.S. Pat. No. 8,361,777, which claims the benefit of EP Application No. 08014141.9 filed Aug. 7, 2008, the entire disclosures of which are incorporated herein by reference.This invention relates to genetically engineered cells, and to proteins and genes useful in the production of tetracycline compounds, to methods of producing tetracycline compounds, and to tetracyclines thereby produced. The present invention is based on the cloning and heterologous expression of genes encoding the chelocardin biosynthetic pathway.Tetracyclines are a large group of drugs with a ...

Подробнее
01-08-2013 дата публикации

Mglu 2/3 agonists

Номер: US20130197079A1
Принадлежит: Eli Lilly and Co

The present invention provides novel mGlu2/3 agonists useful in the treatment of neurological or psychiatric disorders.

Подробнее
15-08-2013 дата публикации

NOVEL CRYSTALLINE FORMS OF (1S,2R)-2-(AMINO METHYL)-N,N-DIETHYL-1-PHENYL CYCLOPROPANE CARBOXAMIDE

Номер: US20130210919A1
Принадлежит:

The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described. 1. A crystalline form of (1S ,2R)-2-(amino methyl)-N ,N-diethyl-1-phenyl cyclopropane carboxamide having an X-ray powder diffraction pattern comprising characteristic peaks at 12.0 , 20.1 and 22.5±0.2 degrees 2θ.2. The crystalline form of claim 1 , wherein the X-ray powder diffraction pattern further comprises a characteristic peak at 32.7±0.2 degrees 2θ.3. The crystalline form of claim 1 , wherein the X-ray powder diffraction pattern further comprises a characteristic peak at 6.0±0.2 degrees 2θ.4. A crystalline form of (1S claim 1 ,2R)-2-(amino methyl)-N claim 1 ,N-diethyl-1-phenyl cyclopropane carboxamide having an X-ray powder diffraction pattern comprising characteristic peaks at 6.0 claim 1 , 12.0 and 20.1±0.2 degrees 2θ.5. The crystalline form of claim 4 , wherein the X-ray powder diffraction pattern further comprises a characteristic peak at 22.5±0.2 degrees 2θ.6. The crystalline form of having a melting endotherm at about 200° C. as determined by differential scanning calorimetry.7. The crystalline form of having a Raman spectrum comprising characteristic peaks at about 695 claim 4 , about 735 and about 1435 cm.8. The crystalline form of having an X-ray diffraction pattern further comprising d spacing peaks at 4.0 and 4.4±0.2 Å.9. A pharmaceutical composition comprising the crystalline form of and a pharmaceutically acceptable carrier.10. A method of treating a disorder that can be managed by inhibition of norepinephrine and serotonin reuptake in a patient in need thereof claim 1 , by administering to said patient an effective amount of a pharmaceutical compositions that comprises the crystalline form of .11. A pharmaceutical composition comprising the crystalline form of and a pharmaceutically acceptable ...

Подробнее
22-08-2013 дата публикации

NASAL FORMULATIONS OF METOCLOPRAMIDE

Номер: US20130213393A1
Принадлежит: Evoke Pharma, Inc.

Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof. 110-. (canceled)11. A pharmaceutical composition comprising metoclopramide , or a pharmaceutically-acceptable salt thereof , a buffer , and benzalkonium chloride; wherein the composition is stable , substantially free of color , and/or substantially clear; and wherein the composition has a pH of above about 4.5.12. The composition of claim 11 , having a starting pH of at least about 4.6.13. The composition of claim 11 , wherein the composition remains stable claim 11 , substantially free of color and/or substantially clear on storage at a temperature of about 25° C. to about 40° C. for at least about 4 weeks claim 11 , at least about 6 weeks claim 11 , at least about 8 weeks claim 11 , at least about 10 weeks or at least about 12 weeks.14. The composition of claim 11 , wherein the buffer is selected from the group consisting of citric acid/phosphate claim 11 , acetate claim 11 , barbital claim 11 , borate claim 11 , Britton-Robinson claim 11 , cacodylate claim 11 , citrate claim 11 , collidine claim 11 , formate claim 11 , maleate claim 11 , McIlvaine claim 11 , phosphate claim 11 , Prideaux-Ward claim 11 , succinate claim 11 , citrate-phosphate-borate (Teorell-Stanhagen) claim 11 , veronal acetate claim 11 , MES (2-(N-morpholino)ethanesulfonic acid) claim 11 , BIS-TRIS (bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane) claim 11 , AD(Original) A (N-(2-acetamido)-2-iminodiacetic acid) claim 11 , ACES (N-(carbamoylmethyl)-2-aminoethanesulfonaic acid) claim 11 , PIPES (piperazine-N claim 11 ,N′-bis(2-ethanesulfonic acid)) claim 11 , MOPSO (3-(N-morpholino)-2-hydroxypropanesulfonic acid) claim 11 , BIS-TRIS PROPANE (1 claim 11 ,3-bis(tris(hydroxymethyl)methylamino)propane) claim 11 , BES (N ...

Подробнее
22-08-2013 дата публикации

NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS

Номер: US20130217660A1
Принадлежит:

Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. 2. The compound of wherein R claim 1 , R claim 1 , and Rare hydrogen; or a pharmaceutically acceptable salt thereof.4. The compound of wherein Ris phenyl claim 1 , wherein phenyl is unsubstituted or substituted with one to three substituents selected from R; or a pharmaceutically acceptable salt thereof.9. The compound of wherein Ris —C(O)—(CH)N(R)and Ris hydrogen; or Rand Rform a morpholine ring; or a pharmaceutically acceptable salt thereof.10. The compound of wherein q is 0 or 1; or a pharmaceutically acceptable salt thereof.12. The compound of wherein{'sup': '1', 'claim-text': (1) hydrogen,', {'sub': 2', '1-6, '(2) —COCalkyl,'}, {'sub': 2', 'p, '(3) —C(O)—(CH)-halogen,'}, {'sub': 2', 'p', '2, 'sup': 'f', '(4) —C(O)—(CH)N(R),'}, {'sub': 2', 'p', '2-6, '(5) —C(O)—(CH)—Ccycloheteroalkyl,'}, {'sub': 2', 'p, '(6) —C(O)—(CH)-heteroaryl, and'}, {'sub': 2', '2-3', '1-6, '(7) —(CH)—O—Calkyl,'}], 'Ris independently selected from the group consisting of{'sub': '2', 'sup': 'b', 'wherein each CH, alkyl, cycloheteroalkyl, and heteroaryl is unsubstituted or substituted with one to two groups independently selected from R;'}{'sup': '2', 'claim-text': (1) hydrogen,', {'sub': '1-6', '(2) —Calkyl, and'}, {'sub': '1-6', '(3) —Calkoxy,'}], 'Ris selected from the group consisting of{'sup': 'c', 'wherein each alkyl and alkoxy is unsubstituted or substituted with one to four substituents selected from R, or'}{'sup': 1', '2, 'sub': '1-3', 'Rand Rform a morpholine ring, wherein the morpholine ring is unsubstituted or substituted with —Calkyl and oxo;'}{'sup': 3', '4', '5, 'R, R, and Rare hydrogen;'}{'sup': '6', 'claim-text': [{'sub': 2 ...

Подробнее
22-08-2013 дата публикации

SYNTHESIS OF ENONE INTERMEDIATE

Номер: US20130217886A1

The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides a more efficient route for preparing the enone intermediate. 1102-. (canceled)104. The method of claim 103 , wherein Ris hydrogen.105. The method of claim 103 , wherein Rand Rare hydrogen.106. The method of claim 103 , wherein Ris —N(R).107. The method of claim 106 , wherein Ris —N(CH).108. The method of claim 103 , wherein n is not 0 claim 103 , and at least one instance of Ris halogen.109. The method of claim 103 , wherein n is not 0 claim 103 , and at least one instance of Ris —NHC(O)R.110. The method of claim 103 , wherein n is not 0 claim 103 , and at least one instance of Ris —OR.111. The method of claim 103 , wherein n is not 0 claim 103 , and at least one instance of Ris cyclic or acyclic claim 103 , substituted or unsubstituted claim 103 , branched or unbranched heteroaliphatic.112. The method of claim 103 , wherein deprotecting the enolate of the ketone (VII) under suitable conditions comprises use of BBror BCl.114. The method of claim 113 , wherein the lipase is Amano Lipase AK.115. The method of claim 113 , wherein the suitable conditions comprise the presence of vinyl acetate.117. The method of claim 116 , wherein the vinyl reagent is a metal vinyl reagent. The present application is a continuation of and claims priority under 35 U.S.C. §120 to U.S. patent application Ser. No. 13/043,742, filed Mar. 9, 2011, which is a continuation of and claims priority under 35 U.S.C. §120 to U.S. patent application Ser. No. 12/833,628, filed Jul. ...

Подробнее
29-08-2013 дата публикации

FATTY AMINES, AMIDOAMINES, AND THEIR DERIVATIVES FROM NATURAL OIL METATHESIS

Номер: US20130225408A1
Принадлежит: STEPAN COMPANY

Fatty amine compositions made from a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives are disclosed. In another aspect, fatty amidoamines made by reacting a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives with an aminoalkyl-substituted tertiary amine are disclosed. The fatty amines or amidoamines are advantageously sulfonated, sulfitated, oxidized, or reduced. In other aspects, the ester derivative is a modified triglyceride made by self-metathesis of a natural oil or an unsaturated triglyceride made by cross-metathesis of a natural oil with an olefin. 1. A fatty amine made from a metathesis-derived C-Cmonounsaturated acid , octadecene-1 ,18-dioic acid , or their ester derivatives.2. A derivative made by one or more of sulfonating claim 1 , sulfitating claim 1 , or oxidizing the fatty amine of .3. The fatty amine of wherein the acid or ester derivative reactant has at least 1 mole % of trans-Δunsaturation.4. The fatty amine of made by reacting the metathesis-derived acid or ester derivative with ammonia or a primary or secondary amine claim 1 , followed by reduction of the resulting fatty amide.5. The fatty amine of wherein the secondary amine is selected from the group consisting of N claim 4 ,N-dimethylamine claim 4 , N claim 4 ,N-diethylamine claim 4 , and N claim 4 ,N-diisopropylamine.6. The fatty amine of made by reducing the metathesis-derived acid or ester derivative to give a fatty alcohol claim 1 , followed by amination of the fatty alcohol.7. The fatty amine of wherein the amination is performed in a single step by reacting the fatty alcohol with ammonia or a primary or secondary amine in the presence of an amination catalyst.9. The fatty amine of wherein the ester derivative is a modified triglyceride made by self-metathesis of a natural oil.10. The fatty amine of wherein the natural oil is selected from the group consisting of soybean oil claim ...

Подробнее
29-08-2013 дата публикации

SOLID FORMS OF AN N-(PHENYLMETHYL) PROPANAMIDE DERIVATIVE AND PROCESSES OF PREPARATION

Номер: US20130225686A1
Принадлежит: MEDICHEM, S.A.

The invention relates to solid forms of the anti-epileptic agent lacosamide (I). The invention also relates to mixtures of solid forms of lacosamide. The invention further relates to mixtures of lacosamide enantiomers crystallized in a conglomerate Form and the use thereof in providing enantiomerically enriched lacosamide, preferably lacosamide enriched with the (R)-enantiomer of lacosamide. 1. A mixture of lacosamide enantiomers crystallized in a conglomerate Form , wherein said mixture of lacosamide enantiomers comprises a crystalline Form of lacosamide selected from the group consisting of lacosamide crystalline Form III characterized by an XRD pattern comprising peaks (2θ) at 6.5 , 8.3 , 10.3 , 12.9 , 15.6 , 16.5 , 17.5 , 19.5 , 21.2 , 22.5 , 24.2 , 24.9 , 27.0 , and 28.5 degrees (±0.2 degrees); lacosamide crystalline Form I characterized by an XRD pattern comprising peaks (2θ) at 8.2 , 10.3 , 12.9 , 15.6 , 16.6 , 17.6 , 19.5 , 20.8 , 21.0 , 21.4 , 25.0 , 25.3 , 26.1 , 27.2 , 30.7 , 31.4 , and 36.6 degrees (±0.2 degrees);lacosamide crystalline Form II characterized by an XRD pattern comprising peaks (2θ) at 5.2, 6.6, 8.1, 10.6, 10.9, 12.5, 15.5, 16.1, 16.8, 17.4, 17.8, 20.5, 21.2, 21.5, 22.1, 22.5, 23.1, 23.8, 24.3, 25.7, 27.1, and 27.6 degrees (±0.2 degrees); lacosamide crystalline Form IV characterized by an XRD pattern comprising peaks (2θ) at 9.5, 14.3, 18.6, 20.0, 23.3 and 25.8 degrees (±0.2 degrees); and lacosamide crystalline Form T characterized by an XRD pattern comprising peaks (2θ) at 8.2, 12.9, 16.5, 19.5 and 24.8 degrees (±0.2 degrees); and mixtures of said crystalline Forms, wherein the mixture includes the (R)-enantiomer of lacosamide, and the (R)-enantiomer of lacosamide is present in an amount of at least about 80% by weight.2. The mixture of lacosamide enantiomers of claim 1 , wherein the (R)-enantiomer of lacosamide is present in an amount of at least about 90% by weight.3. The mixture of lacosamide enantiomers of claim 1 , wherein the (R)- ...

Подробнее
05-09-2013 дата публикации

ROS-Activated Compounds as Selective Anti-Cancer Therapeutics

Номер: US20130230542A1
Принадлежит:

Provided are compounds according to the following Formula I: 2. The compound according to claim 1 , wherein said alkyl claim 1 , aryl claim 1 , and aralkyl substitutions are selected from the group consisting of alkoxyl claim 1 , halo claim 1 , OH claim 1 , CN claim 1 , carboxyl claim 1 , carboxyl ester claim 1 , and substituted or unsubstituted alkyl.3. The compound according to claim 1 , wherein Ris H or alkyl when Ris aryl or aralkyl claim 1 , and wherein Ris H or alkyl when Ris aryl or aralkyl.4. The compound according to claim 1 , wherein Rand Rare each independently selected from the group consisting of H claim 1 , substituted or unsubstituted C-Calkyl claim 1 , and substituted or unsubstituted phenyl; and Ris OH.5. The compound according to claim 1 , wherein the cancer is associated with production of elevated reactive oxygen species.6. The compound according to claim 5 , wherein the cancer is selected from the group consisting of leukemia claim 5 , renal cancer claim 5 , and cancers of the central nervous system.7. The compound according to claim 6 , wherein the leukemia is selected from the group consisting of acute myeloid leukemia claim 6 , acute lymphoblastic leukemia claim 6 , plasmacytoma claim 6 , myeloma claim 6 , myelogenous leukemia claim 6 , acute lymphocytic leukemia claim 6 , acute promyelocytic leukemia claim 6 , and multiple myeloma.9. A method of reducing proliferative capacity in a cell claim 1 , the method comprising contacting the cell with an effective amount of a compound according to .10. The method according to claim 9 , wherein the cell is a mammalian cell.11. The method according to claim 10 , wherein the cell is a cancer cell.12. A method of treating a cancer associated with elevated ROS comprising administering to a subject in need thereof an effective amount of a compound according to .13. The method according to claim 12 , wherein the subject is a mammal.14. The method according to claim 13 , wherein the cancer is selected from ...

Подробнее
05-09-2013 дата публикации

Ethynylbenzene derivatives

Номер: US20130231323A1
Автор: Eric J. Toone, Pei Zhou
Принадлежит: Duke University

Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R 1 , R 2 , R 3 , R 101 , L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.

Подробнее
05-09-2013 дата публикации

OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE

Номер: US20130231385A1
Автор: Ahn Jung-Mo, RAJ Ganesh

The present invention includes bis- and tris-benzamide compounds that block AR signaling and have anticancer activity. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided. 2. The compound of claim 1 , further defined as a compound of formula (A).3. The compound of claim 1 , further defined as a compound of formula (B).4. The compound of claim 2 , wherein X is —NO.5. The compound of claim 3 , wherein X′ is —NO.6. The compound of claim 4 , wherein Rand Rare C-Calkyl claim 4 , C-Calkenyl claim 4 , or C-Calkynyl.7. The compound of claim 4 , wherein Rand Rare optionally substituted C-Carylalkyl.8. The compound of claim 4 , wherein Rand Rare —(CH)—NRR′ or —(CH)—NH(C═NH)NRR′ groups claim 4 , wherein n may be any number between 0 and 6 and R and R′ may be a H claim 4 , C-Calkyl claim 4 , C-Calkenyl claim 4 , C-Calkynyl claim 4 , or C-Coptionally substituted arylalkyl.9. The compound of claim 4 , wherein Rand Rare —(CH)—COOR claim 4 , —(CH)—CONRR′ claim 4 , —(CH)—NRCOR′ claim 4 , —(CH)—NRCOOR′ claim 4 , —(CH)—SOR claim 4 , —(CH)—POR claim 4 , wherein n and m may be any number between 0 and 6 and R and R′ may be a H claim 4 , C-Calkyl claim 4 , C-Calkenyl claim 4 , C-Calkynyl claim 4 , or C-Coptionally substituted arylalkyl.10. The compound of claim 4 , wherein Rand Rare —(CH)—OR claim 4 , —(CH)—SR claim 4 , wherein R may be a H claim 4 , C-Calkyl claim 4 , C-Calkenyl claim 4 , C-Calkynyl claim 4 , or C-Coptionally substituted arylalkyl.11. The compound of claim 4 , wherein Ris C-Coptionally substituted arylalkyl claim 4 , and Ris C-Calkyl claim 4 , C-Calkenyl claim 4 , or C-Calkynyl.12. The compound of claim 4 , wherein Ris C-Calkyl claim 4 , C-Calkenyl claim 4 , or C-Calkynyl claim 4 , and Ris C-Coptionally substituted arylalkyl.13. The compound of claim 4 , wherein Ris —(CH)—NRR′ or —(CH2)-NH(C═NH)NRR′ claim 4 , and Ris —(CH)—COOR claim 4 , —(CH)—SOR claim 4 , —(CH)—POR claim 4 , wherein n and m may be any number between 0 and 6 ...

Подробнее
05-09-2013 дата публикации

(CARBOXYLALKYLENEPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF AND USE OF SAME AS A MEDICAMENT

Номер: US20130231388A1
Принадлежит: SANOFI

The invention relates to (carboxylalkylenephenyl)phenyloxamides and their physiologically tolerated salts, and their use as a medicament. 118-. (canceled)20. (canceled) The invention relates to (carboxylalkylenephenyl)phenyloxamides and their physiologically tolerated salts.Compounds of similar structure have been described in the prior art (see US2005/0124667), as well as the use thereof as antithrombotics.The invention was based on the object of providing compounds which display a therapeutically useful effect. The object was in particular to find novel compounds suitable for the treatment of hyperglycemia and diabetes.The invention therefore relates to compounds of the formula Iin which the meanings arePreference is given to compounds of the formula I in which one or more radicals have the following meanings:Particular preference is given to compounds of the formula I in which one or more radicals have the following meanings:Particular preference is further given to compounds of the formula I in which one or more radicals have the following meanings:In a further embodiment, preference is given to compounds of the formula I in which one or more radicals have the following meanings:In a further embodiment, preference is given to compounds of the formula I in which one or more radicals have the following meanings:In a further embodiment, preference is given to compounds of the formula I in which one or more radicals have the following meanings:In a further embodiment, preference is given to compounds of the formula I in which one or more radicals have the following meanings:Compounds of the formula I preferred in one embodiment are those in which X is —(CH).Compounds of the formula I preferred in one embodiment are those in which X is —(CH)—.Compounds of the formula I preferred in one embodiment are those in which the group —X—COOH is linked in position 3 to the ring.Compounds of the formula I preferred in one embodiment are those in which the group —X—COOH is ...

Подробнее
05-09-2013 дата публикации

USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA

Номер: US20130231393A1
Автор: AUBERT Jérôme
Принадлежит: GALDERMA RESEARCH & DEVELOPMENT

A compound of formula (I): 2. The compound of claim 1 , wherein R6 and R7 are joined together to form a 6 membered heterocycloalkyl ring claim 1 , that is substituted with one heteroatom.3. The compound of claim 2 , wherein the heteroatom is an oxygen.7. The compound of claim 1 , wherein the compound of formula (I) is selected from the group consisting of:1:2-Hydroxy-N,N-dimethyl-3-{2-[(R)-1-(5-methyl-furan-2-yl)-propylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzamide;2:2-Hydroxy-N,N-dimethyl-3-{2-[(4-methyl-furan-2-ylmethyl)-amino]-3,4-dioxo-cyclobut-1-enylamino}benzamide;3:2-Hydroxy-N,N-dimethyl-3-{2-[(4-isopropyl-furan-2-ylmethyl)-amino]-3,4-dioxo-cyclobut-1-enylamino}-benzamide;4:3-{2-[(R)-1-(4-Ethyl-furan-2-yl)-ethylamino]-3,4-dioxo-cyclobut-1-enylamino}-2-hydroxy-N,N-dimethyl-benzamide;5:3-{2-[(R)-1-(4-Ethyl-furan-2-yl)-ethylamino]-3,4-dioxo-cyclobut-1-enylamino}-2-hydroxy-N,N-dimethyl-benzamide;6:3-[2-((R)-1-Furan-2-yl-ethylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N,N-dimethyl-benzamide;7:3-[3,4-Dioxo-2-((R)-1-phenyl-ethylamino)-cyclobut-1-enylamino]-2-hydroxy-N,N-dimethyl-benzamide;8:3-[3,4-Dioxo-2-((R)-1-phenyl-ethylamino)-cyclobut-1-enylamino]-2-hydroxy-N,N-dimethyl-benzamide;9:3-[3,4-Dioxo-2-((R)-1-phenyl-propylamino)-cyclobut-1-enylamino]-2-hydroxy-N,N-dimethyl-benzamide;10:3-[3,4-Dioxo-2-((R)-1-pyridin-2-yl-propylamino)-cyclobut-1-enylamino]-2-hydroxy-N,N-dimethyl-benzamide;11:3-[3,4-Dioxo-2-((R)-1-pyridin-3-yl-propylamino)-cyclobut-1-enylamino]-2-hydroxy-N,N-dimethyl-benzamide;12:3-[3,4-Dioxo-2-((R)-1-pyridin-4-yl-propylamino)-cyclobut-1-enylamino]-2-hydroxy-N,N-dimethyl-benzamide;13:3-(2-Hydroxy-phenylamino)-4-((R)-1-phenyl-propylamino)-cyclobut-3-ene-1,2- dione;14:3-(5-Fluoro-2-hydroxy-phenylamino)-4-((R)-1-phenyl-propylamino)-cyclobut-3-ene-1,2-dione;15:3-(4-Fluoro-2-hydroxy-phenylamino)-4-((R)-1-phenyl-propylamino)-cyclobut-3-ene-1,2-dione;16:3-[3,4-Dioxo-2-((R)-1-phenyl-propylamino)-cyclobut-1-enylamino]-N,N-diethyl-2-hydroxy-benzamide;17:3 ...

Подробнее
05-09-2013 дата публикации

Novel Intermediate for Preparing Tapentadol or Analogues Thereof

Номер: US20130231478A1
Принадлежит:

The invention discloses a novel intermediate for preparing tapentadol and analogues thereof, wherein the structural formula is shown as formula I or II, and the groups are defined as the specification. The invention further discloses a method for preparing the novel intermediate and use of the intermediate for preparing tapentadol and analogues thereof. The invention can remarkably improve the product yield and quality of tapentadol, reduce the production cost, and simplify the production procedure. The preparation process is environment friendly, thus more suitable for the requirements of industrial production. 2. The compound according to claim 1 , wherein Ris selected from Cl claim 1 , methyl claim 1 , OH claim 1 , NHor methoxy.3. The compound according to claim 1 , characterized in that Y is selected from OR claim 1 , wherein Ris selected from methyl claim 1 , ethyl claim 1 , n-propyl or isopropyl.4. The compound according to claim 1 , characterized in that Y is selected from NRR claim 1 , wherein R claim 1 , Rand N form substituted or unsubstituted saturated nitrogen-containing heteorcyclyl containing oxygen or not jointly.5. The compound according to claim 4 , wherein R claim 4 , Rand N form tetrahydropyrrole ring claim 4 , piperidine ring claim 4 , 4-methylpiperidine ring claim 4 , morpholine ring claim 4 , methylpiperazine ring or 4-hydroxypiperidine jointly.6. The compound according to claim 1 , selected from the following compounds:valeryl 2-methyl-3-(3-methoxyphenyl)chloride;methyl 2-methyl-3-(3-methoxyphenyl)sulfovalerate;methyl 2-methyl-3-(3-hydroxyphenyl) ulfovalerate;2-methyl-3-(3-hydroxyphenyl)sulfovaleramide;N,N-dimethyl-2-methyl-3-(3-methoxyphenyl)sulfovaleramide;N,N-dimethyl-2-methyl-3-(3-hydroxyphenyl)sulfovaleramide;N,N-diethyl-2-methyl-3-(3-methoxyphenyl)valeramide;3-(3-methoxyphenyl)-2-methyl-1-(piperidin-1-yl)pentan-1-one;3-(3-methoxyphenyl)-2-methyl-1-(4-methylpiperidin-1-yl)pentan-1-one;3-(3-methoxyphenyl)-2-methyl-1-(morpholin-1-yl)pentan- ...

Подробнее
19-09-2013 дата публикации

Calcium-sensing receptor-active compounds

Номер: US20130244995A1
Принадлежит: Leo Pharma AS

Compounds of general formula (I), their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, and methods of treating diseases with said compounds.

Подробнее
19-09-2013 дата публикации

NOVEL NEUROTRYPSIN INHIBITORS

Номер: US20130245064A1
Принадлежит:

The invention relates to novel acylamino-hydroxy-benzamides of formula (I), wherein Ris phenyl substituted by phenyl, phenoxy, phenylamino or heteroaryl, all optionally further substituted; bicyclic aryl, monocyclic heteroaryl substituted by optionally substituted phenyl, or bicyclic heteroaryl, Ris hydrogen or methyl, and Rand Rhave the meanings indicated in the description. These compounds are useful for the treatment and/or prophylaxis of skeletal muscle atrophy, schizophrenia and Alzheimer's disease, and as cognitive enhancers. 2. The compound according to of formula (I) wherein{'sup': '1', 'sub': 5', '6, 'Ris optionally substituted biphenylyl, phenoxyphenyl or phenylaminophenyl, optionally substituted 1H-benzimidazol-2-yl-phenyl, optionally substituted benzo-C- or C-cycloalkyl or -cycloalkenyl, optionally substituted phenyl-thiophenyl or benzothiophenyl, optionally substituted 1H-benz[d]imidazol-2-yl, optionally substituted indolyl, optionally substituted quinolinyl, or optionally substituted phenyl-1,3-thiazol-2-yl or benzo-1,3-thiazol-2-yl;'}{'sup': '2', 'Ris hydrogen or methyl;'}{'sup': '3', 'Ris alkyl, optionally substituted benzyl, optionally substituted phenylethyl, optionally substituted phenyl; and'}{'sup': '4', 'Ris hydrogen or lower alkyl; or'}{'sup': 3', '4, 'Rand Rtogether with the nitrogen atom, to which they are bound, are optionally substituted pyrrolidino, optionally substituted piperidino, 1,2,3,4-tetrahydro-quinol-1-yl or 1,2,3,4-tetrahydro-isoquinol-2-yl, morpholino, or optionally substituted piperazino.'}3. The compound according to of formula (I) wherein{'sup': '1', 'Ris optionally substituted biphenylyl, phenoxyphenyl or phenylaminophenyl with one to three substituents, wherein the substituents are selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, halo or cyano; 1H-benzimidazol-2-yl-phenyl optionally substituted at nitrogen by methyl or carboxymethyl and at the benzo residue by carboxy, chloro or dichloro; 2-indanyl ...

Подробнее
19-09-2013 дата публикации

CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS

Номер: US20130245084A1
Автор: Månsson Kristoffer
Принадлежит: LEO PHARMA A/S

Compounds of general formula (I) their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, and methods of treating diseases with said compounds. 3. A compound according to claim 1 , wherein Rrepresents methyl.4. A compound according to claim 1 , wherein Rrepresents chloro claim 1 , fluoro claim 1 , methoxy or ethoxy.5. A compound according to claim 1 , wherein Rrepresents chloro claim 1 , fluoro claim 1 , methoxy or ethoxy.6. A compound according to claim 1 , wherein Rrepresents 4-fluoro and Rrepresents 3-methoxy.7. A compound according to claim 1 , wherein Rrepresents chloro and Rrepresents hydrogen.8. A compound according to claim 1 , wherein Rrepresents —C(O)NH claim 1 , Calkoxy claim 1 , haloCalkyl claim 1 , hydroxyCalkyl claim 1 , aminoCalkyl claim 1 , Ccycloalkyl claim 1 , Cheterocycloalkyl comprising 1-3 hetero atoms selected from N and O claim 1 , Cheterocycloalkenyl comprising 1-3 hetero atoms selected from N and O claim 1 , aminosulfonylCalkyl claim 1 , CalkylsulfonylCalkyl claim 1 , CalkylsulfonylaminoCalkyl claim 1 , Cheteroaryl comprising 1-3 hetero atoms selected from N and O claim 1 ,{'sub': 1-4', '1-4', '1-4', '3-6', '2-4', '2-4', '1-4', '1-2', '1-4', '1-2', '1-3', '2-5, 'wherein said Calkoxy, haloCalkyl, hydroxyCalkyl, Ccycloalkyl, Cheterocycloalkyl comprising 1-3 hetero atoms selected from N and O, Cheterocycloalkenyl comprising 1-3 hetero atoms selected from N and O, aminosulfonylCalkyl, CalkylsulfonylCalkyl, CalkylsulfonylaminoCalkyl, Cheteroaryl comprising 1-3 hetero atoms selected from N and O,'}{'sub': 2', '2', '2', '2', '1-4', '2-4', '2-4', '1-4', '1-4', '1-4', '1-4, 'is optionally further substituted with one or more, same or different substituents selected from the group consisting of halogen, trifluoromethyl, hydroxy, mercapto, cyano, ...

Подробнее
19-09-2013 дата публикации

AMINO ACID DERIVATIVES AND ABSORBABLE POLYMERS THEREFROM

Номер: US20130245133A1
Автор: Bezwada Rao S.
Принадлежит: Bezwada Biomedical, LLC.

The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings, highly porous foams, reticulated foams, wound care, cardiovascular applications, orthopedic devices, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers should have a controlled degradation profile. 2. A surgical article or component thereof or polymeric carrier comprising a polymer made of the isocyanate of claim 1 , which is a stent claim 1 , stent coating claim 1 , wound covering claim 1 , burn covering claim 1 , foam claim 1 , highly porous foams claim 1 , reticulated foams claim 1 , tissue engineering scaffold claim 1 , film claim 1 , adhesion prevention barrier claim 1 , implantable medical device claim 1 , controlled drug delivery system claim 1 , suture claim 1 , ligature claim 1 , needle and suture combination claim 1 , surgical clip claim 1 , surgical staple claim 1 , surgical prosthesis claim 1 , textile structure claim 1 , coupling claim 1 , tube claim 1 , support claim 1 , screw claim 1 , pin claim 1 , bone wax formulation claim 1 , tissue adhesive or an adhesion prevention barrier.3. A surgical article or component thereof of claim 2 , wherein a biologically active agent is physically embedded or dispersed into the polymer matrix of the controlled delivery system.4. A pharmaceutical composition comprising a polymeric carrier of and a drug uniformly dispersed therein.5. A polymer containing surgical article or component thereof or polymeric carrier which is a stent claim 1 , stent coating claim 1 , wound covering claim 1 , burn covering claim 1 , foam claim 1 , highly porous foam claim 1 , reticulated foam ...

Подробнее
19-09-2013 дата публикации

PYRAZINO[2,3-D]ISOXAZOLE DERIVATIVE

Номер: US20130245264A1
Принадлежит:

The object of the present invention is to provide a compound which is useful as a production intermediate of pyrazine carboxamide derivative such as 6-fluoro-3-hydroxy-2-pyrazine carboxamide. The present invention provides a pyrazino[2,3-d]isoxazole derivative represented by the formula (I): 2. The pyrazino[2 claim 1 ,3-d]isoxazole derivative according to claim 1 , wherein Y represents —C(═O)R where R represents an alkoxy group or an amino group claim 1 , and the alkoxy group and amino group may be optionally substituted.3. The pyrazino[2 claim 1 ,3-d]isoxazole derivative according to claim 1 , wherein X represents a hydroxyl group claim 1 , a chlorine atom or a fluorine atom.4. The pyrazino[2 claim 2 ,3-d]isoxazole derivative according to claim 2 , wherein X represents a hydroxyl group claim 2 , a chlorine atom or a fluorine atom.5. The pyrazino[2 claim 1 ,3-d]isoxazole derivative according to claim 1 , wherein X represents a fluorine atom or a chlorine atom claim 1 , and Y represents —C(═O)R where R represents an optionally substituted alkoxy group.6. The pyrazino[2 claim 1 ,3-d]isoxazole derivative according to claim 1 , wherein X represents a fluorine atom or a chlorine atom claim 1 , and Y represents —C(═O)R where R represents a methoxy group claim 1 , an ethoxy group claim 1 , an n-propoxy group claim 1 , an isopropoxy group claim 1 , or an n-butoxy group.10. The production method according to claim 8 , wherein X represents a fluorine atom and Y represents —C(═O)R where R represents an optionally substituted alkoxy group.11. The production method according to claim 9 , wherein X represents a fluorine atom and Y represents —C(═O)R where R represents an optionally substituted alkoxy group.12. The production method according to claim 8 , wherein X represents a fluorine atom and Y represents —C(═O)R where R represents a methoxy group claim 8 , an ethoxy group claim 8 , an n-propoxy group claim 8 , an isopropoxy group claim 8 , or an n-butoxy group.13. The ...

Подробнее
19-09-2013 дата публикации

Synthesis of Tripodal Catechol Derivatives Having an Adamantyl Basic Framework for Functionalizing Surfaces

Номер: US20130245269A1
Принадлежит: Justus Liebig Universitaet Giessen

The present invention describes tripodal catechol derivatives with an adamantyl basic framework for the functionalisation of surfaces, methods for their production and use. The remaining fourth bridgehead position is easily suitable to be further functionalised via so-called click reactions, by way of example with biomolecules, dyes, radiomarkers, polyethylene glycol or active agents. The compounds according to the present invention have the general formula X-Ad[(CH 2 ) n —YZ] 3 , wherein A stands for the adamantyl skeleton, X stands for a group —(CH 2 ) p —R 5 , wherein p=0 to 10 and R 5 is selected from —H, —NH 2 , —NO 2 , —OH, —SH, —O—NH 2 , —NH—NH 2 , —N═C═S—, —N═C═O—, —CH═CH 2 , —C≡CH, —COOH, —(C═O)H, —(C═O)R 6 Y stands for —CH 2 —, —CH═CH—, —O—, —S—, —S—S—, —NH—, —O—NH—, —NH—O—, —HC═N—O—, —O—N═CH—, —NR 1 —, -aryl-, -heteroaryl-, —(C═O)—, —O—(C═O)—, —(C═O)—O—, —NH—(C═O)—, —(C═O)—NH—, —NR 1 —(C═O)—, —(C═O)—NR 1 —, —NH—(C═O)—NH—, —NH—(C═S)—NH—, R 1 stands for an alkyl group, R 6 for an alkyl, alkenyl, alkynyl, aryl or heteroaryl group, and Z stands for a catechol derivative. The production of the compounds occurs by reacting a compound X-Ad[(CH 2 ) n —Y′] 3 with a reagent Y″Z to the corresponding compound X-Ad[(CH 2 ) n —YZ] 3 and subsequently purifying the reaction product. Y′ and Y″ are hereby precursors of Y. The compounds according to formula (I) according to the present invention are suitable to be used in a method to functionalise surfaces. The X group of the compounds according to the present invention is suitable to be optionally coupled to an effector, for example, by means of click chemistry.

Подробнее
19-09-2013 дата публикации

Synthesis of Trivalent Flexible Frameworks with Ligands Comprising Catechol Units for Functionalizing Surfaces

Номер: US20130245270A1
Принадлежит: JUSTUS-LIEBIG-UNIVERSITAT GIESSEN

The present invention describes tripodal catechol derivatives with a flexible basic framework for the functionalisation of surfaces, and methods for their production and use. The central atom of the flexible framework is hereby a tertiary aliphatic carbon atom. The remaining fourth bridgehead position is easily suitable to be further functionalised via so-called click reactions, e.g. with biomolecules, dyes, radiomarkers, polyethylene glycol or active agents. 2. The compound according to claim 1 , wherein Y is a bond claim 1 , —CH— claim 1 , —NH—(C═O)— claim 1 , —(C═O)—NH— claim 1 , or —NR—.3. The compound according to claim 1 , wherein n is an integer between 0 and 3.4. The compound according to claim 1 , m is an integer between 0 and 3.7. The compound according to claim 1 , wherein X is —(CH)—R claim 1 , and p is an integer between 0 and 3.8. The compound according to claim 1 , wherein{'sub': 2', 'p, 'sup': '5', 'X is —(CH)—R,'}{'sup': 5', '6', '6', '7', '6, 'sub': 2', '2', '2', '2, 'Ris —H, —OH, —NH, —NO, —NH—NH, —NHR, —NRR, —O—NH, —NH—(C═O)—C≡CH, —C≡CH, —N═C═S, —N═C═O, —COOH, —(C═O)H, or —(C═O)R, and'}p is an integer between 0 and 3.10. The method according to claim 9 , wherein X is a hydrogen atom.11. The method according to claim 9 , wherein{'sub': 2', 'p, 'sup': '5', 'X is —(CH)—R,'}{'sup': 5', '6', '6', '7', '6, 'sub': 2', '2', '2', '2, 'Ris —OH, —NH, —NO, —NH—NH, —NHR, —NRR, —O—NH, —NH—(C═O)—C≡CH, —C≡CH, —N═C═S, —N═C═O, —COOH, —(C═O)H, or —(C═O)R, and'}p is an integer between 0 and 3.12. The method according to claim 11 , wherein Ris protected by a protective group (Pg) prior to reacting the compound with the reagent Y″Z claim 11 , so that the compound Pg-X—C[(CH)—Y′]is reacted with the reagent Y″Z to produce a corresponding compound Pg-X—C[(CH)—YZ].13. (canceled)14. (canceled)15. (canceled) The present invention describes tripodal catechol derivatives with a flexible basic framework for the functionalisation of surfaces, and methods for their production ...

Подробнее
26-09-2013 дата публикации

Compounds And Methods For Treating Candidiasis And Aspergillus Infections

Номер: US20130252964A1
Принадлежит: POLYMEDIX, INC.

The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for killing or inhibiting the growth of a or species or preventing or treating a mammal having candidiasis (oral and/or disseminated) or an infection. 2. The method of wherein each X is S.3. The method of wherein each Ris claim 1 , independently claim 1 , —CH claim 1 , —(CH)—NH claim 1 , —(CH)—NH—C(═NH)NH claim 1 , or —(CH)—NH—C(═O)—R claim 1 , where each n is claim 1 , independently claim 1 , 1 or 2 claim 1 , and each Ris claim 1 , independently claim 1 , H or methyl.49-. (canceled)10. The method of wherein each Ris CF.11. The method of wherein each Vis H and each Vis claim 1 , independently claim 1 , —N—C(═O)—R claim 1 , where each Ris claim 1 , independently claim 1 , —(CH)—NHor —(CH)—NH—C(═NH)NH claim 1 , where each n is claim 1 , independently claim 1 , 1 to 4.1218-. (canceled)19. The method of wherein each Vis H and each Vis —S—R claim 1 , where each Ris —(CH)—NHwhere each n is 2.20. The method of wherein each Ris H claim 1 , —S—(CH)—NH claim 1 , or —S—(CH)—NH—C(═NH)NH claim 1 , where each m is claim 1 , independently claim 1 , 1 to 4.2123-. (canceled)24. The method of wherein:each X is S;{'sup': '1', 'sub': 2', 'n', '2', '2', 'n', '2, 'each Ris, independently, —(CH)—NHor —(CH)—NH—C(═NH)NH, where each n is, independently, 1 to 4;'}{'sup': '2', 'sub': 3', '3', '3, 'each Ris, independently, halo, CF, or C(CH); and'}{'sup': 1', '2', '5', '5, 'sub': 2', 'n', '2, 'each Vis H and each Vis, independently, —S—R, where each Ris, independently, —(CH)—NH, where each n is, independently, 1 to 4.'}2532-. (canceled)3553-. (canceled)5576-. (canceled)7880-. (canceled)82122-. (canceled)124159-. (canceled)161179-. (canceled)181198-. (canceled)200218-. (canceled)220237-. (canceled)239243-. (canceled)245252-. (canceled) The present disclosure was supported by funds from the U.S. Government (NIH/NIDCR Grant No. 2R44DE018371-02) and the U.S. Government may therefore have certain rights in the ...

Подробнее
26-09-2013 дата публикации

STABLE DOSAGE FORMS OF LEVOMILNACIPRAN

Номер: US20130253063A1
Принадлежит: FOREST LABORATORIES HOLDINGS LTD.

The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described. 123-. (canceled)24. A method for treating major depressive disorder in a patient in need thereof , comprising administering to the patient about 120 mg/day of levomilnacipran or a pharmaceutically acceptable salt thereof in one or more sustained release oral dosage forms ,wherein the administering step provides a therapeutic blood plasma level of levomilnacipran or pharmaceutically acceptable salt thereof over approximately a twenty-four hour period to treat major depressive disorder in the patient, and{'sub': max', '0-∞', 'max, 'wherein the administering step provides an average maximum plasma concentration (C) between about 50 ng/mL and about 350 ng/mL of levomilnacipran or pharmaceutically acceptable salt thereof, an AUC between about 1000 ng·hr/mL and about 9000 ng·hr/mL, and a Tof at least 3 hours to the patient, and'}wherein the one or more sustained release oral dosage forms have an X-ray powder diffraction pattern comprising characteristic peaks at about 6.0±0.2 degrees 2θ and at about 12.0±0.2 degrees 2θ.25. The method of claim 24 , wherein the X-ray powder diffraction pattern further comprises characteristic peaks at about 20.1±0.2 degrees 2 θ and/or about 22.5±0.2 degrees 2θ.26. The method of claim 25 , wherein the X-ray powder diffraction pattern comprises characteristic peaks at about 20.1±0.2 degrees 2θ and at about 22.5±0.2 degrees 2θ.2729-. (canceled)30. A method for treating major depressive disorder in a patient in need thereof claim 25 , comprising administering to the patient about 120 mg/day of levomilnacipran or a pharmaceutically acceptable salt thereof in one or more sustained release oral dosage forms claim 25 ,wherein the administering step provides a therapeutic blood plasma level of levomilnacipran or ...

Подробнее
26-09-2013 дата публикации

SEPARATING AGENT FOR PROTEIN PURIFICATION AND PROTEIN PURIFICATION METHOD

Номер: US20130253142A1
Принадлежит: TOSOH CORPORATION

A novel separating agent for protein purification which not only can adsorb proteins in a sufficient amount for protein purification from a low concentration buffer but also can desorb the adsorbed protein easily just by altering the pH of the buffer and a simple and economical method for its production and a method for protein purification using it. 4. The separating agent for protein purification according to claim 1 , wherein the amount of the ligand on the support is at least 100 μmol/ml-support.5. The separating agent for protein purification according to claim 1 , wherein the support is made of a crosslinked polymer.9. The method for producing the separating agent for protein purification according to claim 6 , wherein the activator is carbonyldiimidazole.10. A method for protein purification claim 1 , which comprises dissolving a protein to be purified in a first buffer claim 1 , contacting the resulting protein solution with the separating agent for protein purification as defined in to allow the separating agent to adsorb the protein and then passing a second buffer having a different pH from the first buffer through the separating agent to elute the protein adsorbed on the separating agent. The present invention relates to a novel separating agent having a specific ligand for protein purification, a process for producing it and a protein purification method using it.In recent years, several techniques have been developed and/or optimized to effect separation and purification of target compounds from an aqueous mixture. Such separation and/purification techniques include, for example, ion exchange chromatography, hydrophobic interaction chromatography (HIC) (for example, Non-Patent Document 1), affinity chromatography and the like. The multiplicity of such chromatographic techniques reflects the difficulty in effecting separation and/or purification of target compounds while minimizing the complexity of the separation and/or purification procedure. Each of ...

Подробнее
17-10-2013 дата публикации

SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS

Номер: US20130274249A1
Принадлежит:

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases. 134-. (canceled)36. The method of claim 35 , wherein said cognitive or psychiatric disorder is caused by a dysfunction of a voltage-gated sodium channel.37. The method of claim 35 , wherein said cognitive or psychiatric disorder is caused by a dysfunction of a voltage-gated calcium channel.38. The method of claim 35 , wherein said patient is sensitive to unwanted side effects of MAO inhibitory effects.39. The method of claim 35 , wherein said disorder is a cognitive and/or psychiatric disorder selected from the group consisting of Mild Cognitive Impairment (MCI) claim 35 , depression claim 35 , bipolar disorder claim 35 , mania claim 35 , schizophrenia claim 35 , psychosis claim 35 , anxiety and addiction.40. The method of claim 35 , wherein the compound is administered with at least one other therapeutic agent.41. The method of claim 40 , wherein the at least one other therapeutic agent is an antipsychotic selected from the group consisting of haloperidol claim 40 , risperidone and clozapine.42. The method of claim 41 , wherein the antipsychotic is haloperidol or risperidone.43. The method of claim 35 , wherein the effective amount of the compound administered to the patient in need thereof (i) does not exhibit any MAO-inhibitory activity or (ii) exhibits a reduced MAO-inhibitory activity relative to safinamide or ralfinamide.44. The method of claim 35 , wherein the compound is 2-[2-(3-butoxyphenyl)-ethylamino]-N claim 35 ,N-dimethylacetamide or a pharmaceutically ...

Подробнее
24-10-2013 дата публикации

CATIONIC LIPID

Номер: US20130280305A1
Принадлежит:

The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I) 2. The cationic lipid according to claim 1 , wherein Land Lare —O— or —O—CO— claim 1 , and Rand Rare dodecyl claim 1 , tetradecyl claim 1 , hexadecyl claim 1 , octadecyl claim 1 , icosyl claim 1 , docosyl claim 1 , tetracosyl claim 1 , (Z)-tetradec-9-enyl claim 1 , (Z)-hexadec-9-enyl claim 1 , (Z)-octadec-6-enyl claim 1 , (Z)-octadec-9-enyl claim 1 , (E)-octadec-9-enyl claim 1 , (Z)-octadec-11-enyl claim 1 , (9Z claim 1 ,12Z)-octadec-9 claim 1 ,12-dienyl claim 1 , (9Z claim 1 ,12Z claim 1 ,15Z)-octadec-9 claim 1 ,12 claim 1 ,15-trienyl claim 1 , (Z)-icos-11-enyl claim 1 , (11Z claim 1 ,14Z)-icos-11 claim 1 ,14-dienyl claim 1 , 3 claim 1 ,7 claim 1 ,11-trimethyldodeca-2 claim 1 ,6 claim 1 ,10-trienyl or 3 claim 1 ,7 claim 1 ,11 claim 1 ,15-tetramethylhexadec-2-enyl.3. The cationic lipid according to claim 1 , wherein Land Lare —CO—O— claim 1 , and Rand Rare tridecyl claim 1 , pentadecyl claim 1 , heptadecyl claim 1 , nonadecyl claim 1 , heneicosyl claim 1 , tricosyl claim 1 , (Z)-tridec-8-enyl claim 1 , (Z)-pentadec-8-enyl claim 1 , (Z)-heptadec-5-enyl claim 1 , (Z)-heptadec-8-enyl claim 1 , (E)-heptadec-8-enyl claim 1 , (Z)-heptadec-10-enyl claim 1 , (8Z claim 1 ,11Z)-heptadec-8 claim 1 ,11-dienyl claim 1 , (8Z claim 1 ,11Z claim 1 ,14Z)-octadec-8 claim 1 ,11 claim 1 ,14-trienyl claim 1 , (Z)-nonadec-10-enyl claim 1 , (10Z claim 1 ,13Z)-nonadec-10 claim 1 ,13-dienyl claim 1 , (11Z claim 1 ,14Z)-icos-11 claim 1 ,14-dienyl claim 1 , 2 claim 1 ,6 claim 1 ,10-trimethylundec-1 claim 1 ,5 claim 1 ,9-trienyl or 2 claim 1 ,6 claim 1 ,10 claim 1 ,14-tetramethylpentadec-1-enyl.4. The cationic lipid according to claim 1 , wherein a and b are both 0 or 1.5. The cationic lipid according to claim 1 , wherein Lis a single bond claim 1 , Ris a hydrogen atom claim 1 , methyl claim 1 , pyrrolidin-3-yl claim 1 , piperidin-3-yl claim 1 , piperidin-4- ...

Подробнее
24-10-2013 дата публикации

Chemosensory Receptor Ligand-Based Therapies

Номер: US20130281394A1
Принадлежит: Elcelyx Therapeutics, Inc.

Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention. 4. A composition according to claim 3 , wherein the di- or tripeptide compound of Formula II is selected from the following: γ-Glu-Met(O) claim 3 , γ-Glu-Val-Val claim 3 , γ-Glu-Val-Glu claim 3 , γ-Glu-Val-Lys claim 3 , γ-Glu-Val-Arg claim 3 , γ-Glu-Val-Asp claim 3 , γ-Glu-Val-Met claim 3 , γ-Glu-Val-Thr claim 3 , γ-Glu-γ-Glu-Val claim 3 , γ-Glu-Val-NH claim 3 , γ-Glu-Val-ol claim 3 , γ-Glu-Ser claim 3 , γ-Glu-Tau claim 3 , γ-Glu-Cys(SMe)(O) claim 3 , γ-Glu-Val-His claim 3 , γ-Glu-Val-Orn claim 3 , γ-Glu-Leu claim 3 , γ-Glu-Ile claim 3 , γ-Glu-t-Leu claim 3 , γ-Glu-Cys(S-allyl)-Gly claim 3 , γ-Glu-Val-Asn claim 3 , γ-Glu-Gly-Gly claim 3 , γ-Glu-Val-Phe claim 3 , γ-Glu-Val-Ser claim 3 , γ-Glu-Val-Pro claim 3 , γ-Glu-Ser-Gly claim 3 , γ-Glu-Cys(SMe) claim 3 , γ-Glu-Cys(SNO) claim 3 , γ-Glu-Val-Cys claim 3 , γ-Glu-Val-Gln claim 3 , γ-Glu-Abu-Gly claim 3 , γ-Glu-Cys(SMe)-Gly claim 3 , γ-Glu-Val-Gly claim 3 , γ-Glu-Cys(SNO)-Gly claim 3 , γ-Glu-Cys-Gly claim 3 , γ-Glu-Cys claim 3 , γ-Glu-Met claim 3 , γ-Glu-Thr claim 3 , γ-Glu-Val claim 3 , γ-Glu-Orn claim 3 , γ-Glu-Gly and γ-Glu-Ala.6. A composition comprising a chemosensory receptor ligand having the formula γ-Glu-X-Gly claim 3 , wherein X is selected from: Ala claim 3 , Leu claim 3 , Ile claim 3 , Thr claim 3 , Met claim 3 , Asn claim 3 , Gln claim 3 , Pro claim 3 , hydroxproline claim 3 , Asp claim 3 , Glu claim 3 , Lys claim 3 , Arg claim 3 , His claim 3 , Phe claim 3 , Tyr claim 3 , Trp claim 3 , homoserine claim 3 , citrulline claim 3 , Orn claim 3 , norvaline claim 3 , norleucine claim 3 , and Tau; and wherein the ...

Подробнее
31-10-2013 дата публикации

CYCLOPROPYLAMINE INHIBITORS OF OXIDASES

Номер: US20130289076A1
Принадлежит:

The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer. 24-. (canceled)5. The compound of wherein G is aryl or heteroaryl.6. The compound of wherein G is phenyl claim 5 , indolyl or indazolyl.79-. (canceled)10. The compound of claim 1 , wherein G is phenyl.11. The compound of claim 1 , wherein E is —X═X—.12. The compound of wherein one of X claim 11 , X claim 11 , X claim 11 , and Xis N or C(R2) and the other ones of X claim 11 , X claim 11 , X claim 11 , and Xare each independently C(R2).13. The compound of claim 11 , wherein one of X claim 11 , X claim 11 , Xand Xis N and the other ones of X claim 11 , X claim 11 , Xand Xare each independently C(R2).14. The compound of wherein Xis N claim 13 , and X claim 13 , Xand Xare each independently C(R2).15. (canceled)16. The compound of claim 1 , wherein each R1 is independently chosen from lower alkyl claim 1 , lower alkynyl claim 1 , amido claim 1 , halo claim 1 , lower haloalkyl claim 1 , cyano claim 1 , hydroxyl claim 1 , or alkoxy.1718-. (canceled)19. The compound of claim 1 , wherein each R2 is —H.20. The compound of claim 1 , wherein n is 0 or 1.21. (canceled)22. The compound of claim 1 , wherein the compound of Formula (I) is in the trans configuration in respect of the substituents on the cyclopropyl ring.23. The compound of claim 1 , wherein said compound is chosen from:5-((trans)-2-aminocyclopropyl)-N-(3-chlorophenyl)pyridin-2-amine;5-((trans)-2-aminocyclopropyl)-N-(4-chlorophenyl)pyridin-2-amine;5-((trans)-2-aminocyclopropyl)-N-(4-(trifluoromethyl)phenyl)pyridin-2-amine;5-((trans)-2-aminocyclopropyl)-N-(3-methoxyphenyl)pyridin-2-amine;5-((trans)-2-aminocyclopropyl)-N-(4-methoxyphenyl)pyridin-2-amine;5-((trans)-2-aminocyclopropyl)-N-p-tolylpyridin-2-amine;5-((trans)-2-aminocyclopropyl)-N-m-tolylpyridin-2-amine;4-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino ...

Подробнее
31-10-2013 дата публикации

Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators

Номер: US20130289122A1
Принадлежит: Newron Pharmaceuticals SpA

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases.

Подробнее
31-10-2013 дата публикации

PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARATION PROCESSES AND USES THEREOF

Номер: US20130289124A1
Принадлежит: YINGU PHARMACEUTICAL CO., LTD

Phenylcyclobutylamide derivatives and their optical isomers, the preparing processes and the uses thereof, which includes the compounds of formula (I), their pure stereoisomers and their pharmaceutically acceptable salts. In formula (I), R is H, formacyl, acetyl, haloacetyl, benzoyl, benzyloxy carbonyl (Cbz), t-butoxy carbonyl (Boc), or 9-fluorenyl methoxyl carbonyl (Fmoc). The present novel compounds have pharmaceutical activity and are prepared by condensation reaction of racemic, levo- or dextro-demethyl Sibutramine and racemic or D/L isoleucine under a mild condition. It is demonstrated that the present compounds have effect of losing weight to obese mode rats in different level and the effect is better than Sibutramine by the animal experiments. So the medicaments prepared by the present compounds or the medicaments prepared by the compositions of the present compounds and other pharmaceutical activity compounds may be used for treating obesity. 2. The method of claim 1 , wherein the acyl group containing 1 to 16 carbon atoms is formacyl claim 1 , acetyl claim 1 , haloacetyl claim 1 , benzoyl claim 1 , benzyloxycarbonyl (Cbz) claim 1 , t-butyloxycarbonyl (Boc) claim 1 , or 9-fluorenylmethoxylcarbonyl (Fmoc).3. The method of claim 1 , wherein R is H.4. The method of claim 1 , wherein the compounds are at least one selected from the group consisting of 2-amino-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-3-methylpentanamide and the optical isomers thereof: (2S claim 1 ,3S)-2-amino-N-{(S)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-3-methyl pentanamide; (2S claim 1 ,3S)-2-amino-N-{(R)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-3-methylpentanamide; (2R claim 1 ,3R)-2-amino-N-{(S)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-3-methylpentanamide; (2R claim 1 ,3R)-2-amino-N-{(R)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-3-methyl pentanamide; and the pharmaceutically acceptable salts of these compounds.5. The method of claim 4 , wherein the ...

Подробнее
07-11-2013 дата публикации

Substituted tetracyclines

Номер: US20130296279A1
Автор: Adam Morgan
Принадлежит: Concert Pharmaceuticals Inc

The invention in one embodiment is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention is also directed to a composition comprising the compound of formula I or a pharmaceutically acceptable salt, and methods of treating the indications listed herein.

Подробнее
14-11-2013 дата публикации

CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS

Номер: US20130303545A1
Принадлежит:

The invention relates to methods and compositions for the treatment or prevention of protein conformation disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing a protein conformation disorder, such as, e.g., Huntington Disease. 121-. (canceled)22. A method of treating or preventing a cognitive symptom in an individual having a protein conformation disorder comprising identifying an individual in need of such treatment and administering to said individual for a sufficient period of time an amount of an LSD1 inhibitor sufficient to improve the cognitive symptom or reduce the rate of decline of the cognitive symptom thereby treating or preventing said cognitive symptom.23. The method of claim 22 , wherein said protein conformation disorder is a CAG expansion disorder claim 22 , Alzheimer Disease or Parkinson Disease.2427-. (canceled)28. The method of claim 23 , wherein said CAG expansion disorder is Huntington disease claim 23 , Kennedy Disease claim 23 , Spinocerebellar Ataxia 1 claim 23 , Spinocerebellar Ataxia 2 claim 23 , Spinocerebellar Ataxia 3 claim 23 , Spinocerebellar Ataxia 6 claim 23 , Spinocerebellar Ataxia 7 claim 23 , or Spinocerebellar Ataxia 17.29. A method of treating or preventing a motor symptom in an individual having a protein conformation disorder comprising identifying an individual in need of such treatment and administering to said individual for a sufficient period of time an amount of an LSD1 inhibitor sufficient to reduce the rate of decline in said motor symptom thereby treating or preventing said motor symptom.30. The method of claim 29 , wherein said protein conformation disorder is a CAG expansion disorder claim 29 , Alzheimer Disease claim 29 , or Parkinson Disease.3135-. (canceled)36. A method of increasing longevity in an individual having a protein conformation disorder comprising identifying an individual in need of such treatment and administering to said individual for a sufficient ...

Подробнее
14-11-2013 дата публикации

Enzyme inhibitors

Номер: US20130303576A1
Принадлежит: Chroma Therapeutics Ltd

Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent ═CH— or ═N—; W is —CH═CH—Or —CH 2 CH 2 —; R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R2 and R3 are selected from the side chains of a natural or non-natural alpha amino acid, provided that neither R 2 nor R 3 is hydrogen, or R 2 and R 3 , taken together with the carbon to which they are attached, form a 3-6 membered saturated cycloalkyl or heterocyclyl ring; Y is a bond, —C(═O)—, —S(═O) 2 —, —C(═O)O—, —C(═O)NR′—, —C(═S)—NR′, —C(═NH)NR′ or —S(═O) 2 NR— wherein R′ is hydrogen or optionally substituted C 1 -C 6 alkyl; L 1 is a divalent radical of formula -(Alk 1 ) m (Q) n (Alk 2 ) p - wherein m, n, p, Q. Alk 1 and Alk 2 are as defined in the claims; X 1 represents a bond; —C(═O); or —S(═O) 2 —; —NR 4 C(═O)—, —C(═O)NR 4 —, —NR 4 C(═O)NR 5 —, —NR 4 S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R 4 and R 5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; and z is 0 or 1.

Подробнее
14-11-2013 дата публикации

COMPOSITIONS FOR PREVENTION/PROPHYLACTIC TREATMENT OF POISON IVY DERMATITIS

Номер: US20130303582A1
Принадлежит:

The present invention, in one or more embodiments, comprises water-soluble derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecylcatechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising water soluble urushiol esters of general formula (I) 2. The method of claim 1 , wherein the at least one ester is administered parenterally claim 1 , transdermally or transnasally.3. The method of desensitizing a subject according to claim 1 , wherein Ris pentadecyl.4. The method of desensitizing a subject according to claim 1 , wherein Ris heptadecyl.5. The method of desensitizing a subject according to claim 1 , wherein Ris nonadecyl.6. The method of desensitizing a subject according to claim 1 , wherein the esters are esters of amino acids or combinations of amino acids or derivatives of an amino acid with a dicarboxylic acid.7. The method of desensitizing a subject according to claim 1 , wherein the esters are esters of dicarboxylic acids or dicarboxylic acid derivatives.8. The method of desensitizing a subject according to claim 1 , wherein the esters are phosphate or sulfate esters.9. The method of desensitizing a subject according to claim 1 , wherein the esters are salt-forming carbamates.10. The method of desensitizing a subject according to claim 1 , wherein the at least one ester is heptadecyl catechol phenyl alaninate ester claim 1 , 3-hepta-1 claim 1 ,2-phenylene bis(4-aminophenyl) butanoate claim 1 , heptadecyl catechol indole-propionate ester claim 1 , heptadecyl catechol-β-alaninate ester claim 1 , pentadecyl catechol valininate ester claim 1 , ...

Подробнее
21-11-2013 дата публикации

Amide derivative, pest control agent containing the amide derivative, and use of the amide derivative

Номер: US20130310459A1
Принадлежит: Mitsui Chemicals Agro Inc

An amide derivative represented by the following Formula (1) is provided as an amide derivative showing a significantly excellent effect for a pest control action. In the following Formula (1), A represents a carbon atom, a nitrogen atom, or the like, and K represents a non-metal atomic group necessary for forming a cyclic linking group derived from benzene or a heterocyclic. X represents a halogen atom or the like; n represents an integer of from 0 to 4. R 1 and R 2 represent hydrogen atoms, alkyl groups, or the like. T represents —C(=G 1 )-Q 1 or —C(=G 1 )-G 2 Q 2 , and G 1 to G 3 each represent oxygen atoms or the like. Q 1 and Q 2 each represent a hydrogen atom, an alkyl group, an aryl group, or the like. Y 1 and Y 5 each represent a halogen atom or the like, Y 2 and Y 4 each represent a hydrogen atom or the like, and Y 3 represents a C2-C5 haloalkyl group.

Подробнее
28-11-2013 дата публикации

Process for the preparation of lacosamide

Номер: US20130317109A1
Принадлежит: CAMBREX KARLSKOGA AB

There is provided a process for the preparation of Lacosamide (which is a useful medicament) of formula I, which comprises an enantioselective enzymatic acylation.

Подробнее
28-11-2013 дата публикации

COMPOUND, KINESIN SPINDLE PROTEIN INHIBITOR, AND APPLICATION THEREOF

Номер: US20130317110A1
Принадлежит: FUJITSU LIMITED

A compound represented by the following General Formula (I): 3. The compound according to claim 1 ,{'sub': 1', '2', '1', '2, 'wherein in the compound represented by General Formula (I), Ror Ris or both Rand Rare an ethyl group or a methyl group, and X represents a hydrogen atom, a fluorine atom or a chlorine atom.'}7. The pharmaceutical composition according to claim 6 ,wherein the disorder mediated at least partially by the kinesin spindle protein is a cell proliferative disease.8. The pharmaceutical composition according to claim 6 ,wherein the disorder mediated at least partially by the kinesin spindle protein is a cell proliferative disease, andwherein the cell proliferative disease is a cancerous disease.9. The pharmaceutical composition according to claim 6 ,wherein the disorder mediated at least partially by the kinesin spindle protein is a cell proliferative disease,wherein the cell proliferative disease is a cancerous disease, andwherein the cancerous disease is lung cancer, bronchial cancer, prostate cancer, breast cancer, pancreas cancer, colon cancer, rectal cancer, small intestinal cancer, thyroid cancer, esophageal cancer, oral cancer, pharyngeal cancer, larynx cancer, stomach cancer, liver cancer, intrahepatic bile duct cancer, kidney cancer, renal pelvis cancer, bladder cancer, uterine corpus cancer, uterocervical cancer, ovary cancer, conjunctival cancer, lacrimal cancer, palpebral cancer, multiple myeloma, brain tumor, non-Hodgkin's lymphoma, melanoma, trophoblastic colon adenoma, acute myelocytic leukemia, chronic myelocytic leukemia, lymphatic leukemia, myelocytic leukemia, or any combination thereof.10. The pharmaceutical composition according to claim 6 , further comprising a pharmacologically acceptable carrier.11. The pharmaceutical composition according to claim 6 , further comprising at least one drug used for prevention or treatment of cancer.13. The method according to claim 12 ,wherein the cells are cells in vivo or cultured cells.14. ...

Подробнее